

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07K 14/47, C12N 5/10, 15/12, 15/62	A1	(11) International Publication Number: WO 96/17866 (43) International Publication Date: 13 June 1996 (13.06.96)
(21) International Application Number: PCT/US95/15144 (22) International Filing Date: 20 November 1995 (20.11.95) (30) Priority Data: 08/353,550 9 December 1994 (09.12.94) US (71) Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: WILLIAMS, Lewis, T.; 114 Avenida Miraflores, Tiburon, CA 94920 (US). KAVANAUGH, William, Michael; 205 Laverne Avenue, Mill Valley, CA 94941 (US). (74) Agent: BERLINER, Robert; Robbins, Berliner & Carson, 5th floor, 201 N. Figueroa Street, Los Angeles, CA 90012-2628 (US).		(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, LS, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: NOVEL PROTEIN DOMAIN WHICH BINDS TYROSINE PHOSPHORYLATED PROTEINS (57) Abstract The present invention generally relates to novel protein domains which bind to tyrosine-phosphorylated proteins. More particularly, the present invention provides non-SH2 protein domains that bind phosphotyrosine. The present invention also provides various composite polypeptides comprising these domains, such that these composite polypeptides retain the ability to bind tyrosine phosphorylated proteins. It also provides nucleic acids encoding these polypeptides. Typically, these nucleic acids may also comprise a promoter for expression, and a segment encoding fusion peptides on the amino or carboxy terminus of the expressed composite protein. Also included within the present invention are methods of preparing these polypeptides and cells capable of expressing them. Also provided are methods of using these polypeptides in research, diagnostic and therapeutic applications.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

NOVEL PROTEIN DOMAIN WHICH BINDS TYROSINE PHOSPHORYLATED PROTEINS

5 The present invention generally relates to
novel protein domains that specifically bind to tyrosine-
phosphorylated proteins. More particularly, the present
invention provides non-SH2 protein domains that bind
phosphotyrosine. The present invention also provides
10 various composite polypeptides comprising these domains,
such that these composite polypeptides retain the ability
to bind tyrosine phosphorylated proteins. It also
provides nucleic acids encoding these polypeptides.
Typically, these nucleic acids can also comprise a
15 promoter for expression, and a segment encoding fusion
peptides on the amino or carboxy terminus of the
expressed composite protein. Also included within the
present invention are methods of preparing these
polypeptides and cells capable of expressing them. Also
20 provided are methods of using these polypeptides in
diagnostic and therapeutic applications.

 The present invention was made with U.S.
Government support under Grant Nos. R01 HL32898 and K11
HL02714, awarded by the National Institutes of Health.
25 The government has certain rights in this invention.

BACKGROUND OF THE INVENTION

 Receptor signaling pathways are the subject of
widespread research efforts. A better understanding of
30 these signaling pathways will lead to the design of new
and more effective drugs in the treatment of many
diseases. Of particular interest are the growth factor
and related receptor signaling pathways and their role in
cell growth and differentiation. Binding of a particular
35 growth factor to its receptor on the cell plasma membrane
can stimulate a wide variety of biochemical responses,
including changes in ion fluxes, activation of various
kinases, alteration of cell shape, transcription of

various genes and modulation of enzymatic activities in cellular metabolism.

In particular, upon binding an external ligand, a receptor may undergo auto-phosphorylation of specific tyrosine residues, and/or may phosphorylate other proteins. This tyrosine phosphorylation creates binding sites for cytoplasmic signaling proteins which have specific domains that recognize the phosphorylated tyrosine and adjacent residues. Once bound, these signaling proteins may in turn be activated. The activated signaling proteins then may effect downstream processes. Pawson and Gish, *Cell* 71:359-362 (1992).

SH2 (which stands for Src Homologous) domains are amino acid sequences that are similar to a 100-residue, non-catalytic region of the Src tyrosine kinase and are present in various signaling molecules. Sadowski et al., *Mol. Cell. Biol.* 6, 4396 (1986). SH2 domains are the functional protein motifs that bind tyrosine-phosphorylated targets by recognizing phosphotyrosine and specific adjacent residues. J.A. Escobedo et al., *Mol. Cell. Biol.* 11, 1125 (1991); L.C. Cantley et al. *Cell* 64, 281 (1991); T. Pawson and G.D. Gish *Cell* 71, 359 (1992); S. Zhou et al. *Cell* 72, 767 (1993); G. Waksman, S.E. Shoelson, N. Pant, D. Cowburn, J. Kuriyan *Cell* 72, 779 (1993). Activation of tyrosine kinases by growth factors, cytokines, and oncogenic agents therefore serves as a switch for assembling SH2 domain-containing proteins with their tyrosine-phosphorylated targets in signaling complexes, in which downstream effectors are activated.

The use of tyrosine kinase binding domains, including SH2 domains, has been discussed in methods for identifying targets of tyrosine kinases in cells, and thus identifying intermediates in cell signaling pathways. See, PCT Patent Application No. WO 92/13001, to Schlessinger et al.

The specific use of SH2 domains and subdomains in affecting the SH2 phosphorylated ligand regulatory scheme, or screening for compounds which affect SH2 binding in the SH2 phosphorylated regulatory scheme, as well as in assaying for the presence of SH2 binding phosphoproteins, has generally been described. See, U.S. Patent No. 5,352,660 to A. J. Pawson.

Specific SH2 containing proteins include the products of the SHC gene. The SHC (which stands for SH2, Collagen) gene encodes a transforming protein expressed as 46- and 52-kD proteins, that are tyrosine phosphorylated in response to a number of growth factors, e.g., PDGF, EGF and FGF, and have been implicated as mediators of signaling from growth factor receptor and non-receptor tyrosine kinases to Ras. G. Pelicci et al. *Cell* 70, 93-104 (1992); M. Rozakis-Adcock et al. *Nature*, 360:689 (1992).

Thus, a great deal of attention has been directed toward studying these SH2 domains and their role in cell signaling pathways. However, SH2 domains, and the proteins which comprise them, are not the only phosphotyrosine binding mediators of such pathways. Accordingly, the study of these pathways, and the ability to control them requires identification and characterization of other phosphotyrosine binding domains. The present invention meets these and other needs.

SUMMARY OF THE INVENTION

One aspect of the present invention provides an isolated polypeptide comprising a non-SH2 phosphotyrosine binding ("PTB") domain. Such polypeptides are capable of binding a tyrosine-phosphorylated protein through the non-SH2 PTB domain. Preferably, the isolated polypeptide comprises an amino acid sequence that is substantially homologous to the amino acid sequence of the SHC protein PTB domain, and more preferably the polypeptide comprises

the amino acid sequence of either the SHC PTB domain or a SHC-like ("SCK") PTB domain. The polypeptide can be in the form of a fusion protein, or can comprise a detectable group attached thereto.

5 In an alternative embodiment is provided an isolated nucleic acid comprising a segment which encodes a non-SH2 PTB domain. Preferably, the nucleic acid comprises a nucleotide sequence that is substantially homologous to the nucleotide sequence which encodes the
10 SHC PTB domain, and more preferably, comprises the nucleotide sequence encoding the SHC PTB domain or SCK PTB domain. The nucleic acid sequence may further comprise a segment which encodes a heterologous protein fused to the PTB domain encoding segment. Also provided
15 are expression vectors comprising the above nucleic acids operably linked to a promoter sequence.

Also provided are methods of preparing the polypeptides of the present invention. The methods comprise inserting the nucleic acids of the present
20 invention in a suitable expression vector, transfecting a host cell with the expression vector, such that the cell is capable of expressing the non-SH2 PTB domain, and recovering the non-SH2 PTB domain.

Further provided are nucleic acid probes,
25 comprising at least 15 consecutive nucleotides of the nucleotide sequence which encodes the SHC or SCK PTB domains, and wherein the probes are linked to a detectable group.

Also provided is a method of determining
30 whether a protein is a phosphorylated ligand of a PTB domain. The method comprises contacting the protein with a polypeptide of the present invention and detecting the binding of the polypeptide to the protein. The binding of the polypeptide to the protein is indicative that the
35 protein is a phosphorylated ligand of the PTB domain.

In a related aspect, the present invention provides a method of determining whether a test compound

is an antagonist of a growth factor activation signaling pathway in a cell. The method comprises contacting the cell with the test compound in the presence of a growth factor. The cells are then lysed and the cell lysate is
5 assayed to determine whether any protein in the lysate is a phosphorylated ligand to a PTB domain. The absence of the phosphorylated ligand is indicative that the compound is an antagonist of the growth factor activation signaling pathway.

10 In another related aspect, the invention provides a method of determining if a test compound is an agonist or antagonist of a PTB domain/phosphorylated ligand regulatory system. The method comprises incubating the test compound with a polypeptide
15 comprising a PTB domain, and a phosphorylated ligand which is capable of interacting with said PTB domain to form a PTB domain/phosphorylated ligand complex, under conditions which permit the formation of said complex. The amount of PTB domain/phosphorylated ligand complex
20 formed is determined, and compared to the amount of PTB domain/phosphorylated ligand complex formed in the absence of the test compound. The increase or decrease in the amount of complex formed in the presence of the test compound over the amount of complex formed in the
25 absence of the test compound is indicative that the test compound is an agonist or antagonist of the PTB domain/phosphorylated ligand regulatory system.

In a further aspect is provided a method of blocking growth factor dependent stimulation of cells,
30 comprising contacting the cells with an effective amount of the polypeptides of the present invention.

In an additional embodiment is provided method of obtaining substantially pure phosphorylated ligand to a PTB domain from a mixture of different proteins
35 comprising contacting the mixture of different proteins with a PTB domain immobilized on a solid support, whereby the phosphorylated ligand is bound to the PTB domain.

The solid support is washed to remove unbound proteins, and the phosphorylated ligand is then eluted from the solid support.

Also provided is a method for treating a patient suffering from a proliferative cell disorder, comprising administering to said patient, an effective amount of the polypeptide of the present invention. Alternatively, the method may comprise explanting cells from the patient, transfecting the cells with a nucleic acid encoding a peptide comprising a non-SH2 PTB domain, selecting for cells which have incorporated said nucleic acid, and reimplanting the cells into the patient. Such proliferative cell disorders include, e.g., atherosclerosis, inflammatory joint disease, psoriasis, restinosis, and cancer.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an immunoblot using antibody to phosphotyrosine. The blot illustrates the association of SHC with growth factor stimulated (PDGF and FGF) 145-kD tyrosine-

phosphorylated proteins *in vivo*, immunoprecipitated with pre-immune serum ("PRE") or antiserum to SHC ("anti-SHC") and immunoblotted with antibody to phosphotyrosine. The black arrows indicate the 52-kD SHC protein and a 66-kD SHC-related protein seen in fibroblasts. The pp145 proteins are indicated by the open arrows. Each lane contains equal amounts of SHC as determined by immunoblotting with antiserum to SHC.

Figure 2 shows binding of SHC to pp145. Panel A shows the binding of full-length SHC to proteins in cell lysates ("LYSATE") or in anti-SHC immunoprecipitates ("SHC IP") from quiescent (-) or PDGF-stimulated (+) Balb/c 3T3 cells. Panel B shows pp145 protein in lysates or anti-SHC immunoprecipitates from PDGF-stimulated fibroblasts, blotted with ³²P-labeled SHC (left), SHC in which the SH2 domain had been deleted ("SHCΔSH2",

residues 1 to 377, middle) or the isolated SHC SH2 domain ("SH2", residues 378 to 473, right). Panel C shows the deletional mapping of the pp145-binding domain on the SHC protein. Fragments of SHC corresponding to the indicated
5 residues were prepared as ³²P-labeled GST fusion proteins and as probes as described above. The organization of the SHC protein is shown, including the two translation start sites, the GRB2 binding site ("GRB2"), and the PTB domain (shown as the cross-hatched box), the collagen
10 domain (shown as the vertically hatched box) and the SH2 domain (shown as the lightly shaded or white region). Also shown are blots of anti-SHC immunoprecipitates from PDGF-stimulated fibroblast lysates using three representative probes. Panel D shows the binding of the
15 PTB domain. GST-SHCΔSH2 fusion protein containing an IHA epitope tag was incubated with lysate of activated B cells and then purified by immunoaffinity chromatography with monoclonal antibody to IHA ("PTB-IHA+lysate"), binding is shown by the absence of pp145 in the
20 flowthrough, and its presence in the eluate. The controls ("Lysate alone" and "PTB-IHA alone") show no binding. The starting material ("Start"), column flow-through ("Flowthrough") and SDS eluates ("Eluate") were analyzed by blotting with ³²P-labeled PTB domain
25 probe as described above. The arrows within the lanes indicate the correct line-up of the labels for the lanes.

Figure 3 shows the involvement of phosphotyrosine in binding of SHC to pp145. In Panel A, the proteins in anti-SHC immunoprecipitates from
30 PDGF-stimulated fibroblasts were immobilized on nitrocellulose and treated with tyrosine-specific phosphatases ("PTPase") in the presence or absence of the PTPase inhibitor sodium orthovanadate ("PTPase + vanadate"). The filters were then blotted with
35 ³²P-labeled GST-SHC ("32P-SHC BLOT") (top) or immunoblotted with antibody to phosphotyrosine ("APT BLOT") (bottom). In Panel B, lysates from

PDGF-stimulated cells were blotted with ^{32}P -labeled GST-SHC in the presence of the indicated concentrations of phosphotyrosine ("P-TYR") or phosphoserine ("P-SER").

Figure 4 shows a comparison of the amino acid sequences of SHC and SCK. Shown is a comparison of residues 11 to 432 of SHC with a SCK partial clone. Bold, uppercase letters represent identical residues. The PTB domains of SHC (Figure 2, Panel C) and SCK are enclosed in boxes; the SH2 domains are underlined. Asterisks mark a FLVRES-like sequence in the PTB domain. Abbreviations for the amino acid residues are: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G, Gly; H, His; I, Ile; K, Lys; L, Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.

Figures 5A, 5B and 5C show the nucleotide sequence and deduced amino acid sequence of the partial SCK protein, including the PTB domain. The termini of the SCK PTB domain and the nucleotide sequence encoding that domain are indicated by the arrows (nucleotide position 100-651 as shown in the figure).

Figures 6A, 6B and 6C show the nucleotide sequence and deduced amino acid sequence of the SHC protein, including the 186 amino acid SHC PTB domain, corresponding to amino acid residues 46 to 232 of SHC that bind to ppl45. The termini of the SHC PTB domain are indicated by the arrows (nucleotide position 136 through 693, as shown in the figure).

DESCRIPTION OF THE PREFERRED EMBODIMENT

I. General Description

A. SHC Protein

As discussed previously, the SHC gene encodes two transforming proteins that are tyrosine phosphorylated in response to a number of growth factors, and have been implicated as mediators of signaling from growth factor receptor and non-receptor tyrosine kinases to Ras.

The full length nucleotide sequence, and deduced amino acid sequences of the SHC gene have been previously described. See Pelicci et al., *Cell* 70:93-104 (1992). Furthermore, identified within this sequence were 1) an SH2 domain at the COOH-terminus, which binds tyrosine phosphorylated targets, such as activated growth factor receptors, 2) a region of similarity to human alpha-1 collagen in the middle of the molecule that contains a binding site for the GRB2 adapter protein, and 3) a 232-residue NH₂-terminus with previously unknown function. Surprisingly, however, it has now been discovered that within this NH₂-terminal region of the SHC protein is a domain which is capable of binding to tyrosine-phosphorylated proteins in a manner similar to that of the SH2 domains. This phosphotyrosine binding domain ("PTB") binds specifically to the tyrosine phosphorylated form of its target protein. Furthermore, the amino acid sequence of the phosphotyrosine binding domain ("PTB") is not similar to that of any member of the known SH2 domain family.

1. Analysis of SHC Binding

Identification of the PTB domain began with investigation of proteins that co-immunoprecipitated with the SHC protein in growth factor-stimulated cells. Several tyrosine-phosphorylated proteins of approximately 145 kD (collectively referred to as pp145) were present in anti-SHC immunoprecipitates from cells treated with either platelet-derived growth factor (PDGF) or fibroblast growth factor (FGF), but not in anti-SHC immunoprecipitates from unstimulated cells (Figure 1). Similar tyrosine phosphorylated protein(s) were associated with SHC in B cells stimulated with antibodies to IgM, in activated T cells, in HepG2 hepatoma cells stimulated with interleukin 6 (IL6), and in CCE embryonic stem cells stimulated with leukemia inhibitory factor (LIF). The number and electrophoretic mobility of the

pp145 proteins varied slightly among different cell types. These may represent different proteins or the same protein with different amounts of phosphorylation. All of these proteins appear to bind to SHC in a similar manner. The pp145 proteins in fibroblasts or in B cells were not recognized by immunoblotting with antibodies to SHC, phospholipase C gamma, Ras guanosine triphosphatase-activating protein (Ras GAP), the guanine nucleotide exchange factor Son-of-Sevenless (SOS), insulin receptor substrate 1 (IRS-1), the guanine nucleotide exchange factor C3G, the transforming protein eps15 or the PDGF or FGF receptors.

To characterize binding of SHC to pp145, proteins were separated from cell lysates by SDS-polyacrylamide gel electrophoresis (PAGE), transferred to nitrocellulose and incubated with ³²P-labeled glutathione S-transferase (GST)-SHC fusion protein. ³²P-labeled GST-SHC bound specifically to three proteins of approximately 180, 145 and 120 kD from lysates of PDGF-stimulated fibroblasts, but did not bind any proteins from lysates of unstimulated cells (Figure 2, Panel A). The 180-kD band co-migrated with the autophosphorylated PDGF receptor; the 145-kD band co-migrated with the major pp145 protein identified in Figure 1; the identity of the 120-kD protein is unknown. The ³²P-GST-SHC probe also bound 145-kD proteins present in anti-SHC immunoprecipitates from PDGF-stimulated cells, but did not bind any proteins in immunoprecipitates from unstimulated cells (Figure 2, Panel A). Therefore, the ³²P-SHC probe apparently binds to the same 145-kD protein or proteins that associate with SHC *in vivo*. These experiments demonstrated that SHC binds pp145 directly, and that interaction of SHC and pp145 *in vitro* requires PDGF stimulation *in vivo*.

2. Deletional Analysis of SHC Protein

To map the region of the SHC protein responsible for binding to pp145, ³²P-labeled GST-SHC probes were prepared containing deletions of various domains. Deletion of the SH2 domain of SHC eliminated binding to the p180 and p120 proteins in lysates of PDGF-stimulated cells but did not affect binding to pp145 in either cell lysates or in anti-SHC immunoprecipitates (Figure 2, Panel B). Further, the isolated SHC SH2 domain bound to p180 and p120, but not to pp145 (Figure 2, Panel B). Therefore, binding of SHC to p120 and p180 was due to the SH2 domain, but binding of SHC to pp145 did not require the SH2 domain. By further deletional analysis, a 186 amino acid fragment representing residues 46 to 232 of SHC that bound pp145 (Figure 2, Panel C) was identified. This fragment bound specifically to pp145, and not to any other proteins in the nitrocellulose filter binding assays of lysates or anti-SHC immunoprecipitates from cells stimulated with PDGF, FGF, or from activated B cells. This region of the SHC protein also specifically bound pp145 in solution binding assays (Figure 2, Panel D). The pp145-binding domain (hereafter referred to as "the PTB domain") is located in the NH₂-terminal portion of the SHC protein, for which no function had been previously assigned.

Because both SHC and pp145 are tyrosine phosphorylated in growth factor-stimulated cells, the binding properties of these two molecules, and how they were influenced by tyrosine phosphorylation was examined further. Phosphotyrosine was not detected on immunoblots of baculovirus-derived GST-SHC protein probe using antibody to phosphotyrosine, and treatment of the GST-SHC probe with tyrosine-specific phosphatases had no effect on binding to pp145. Therefore, tyrosine phosphorylation of SHC is not required for binding. To investigate the relationship of phosphorylation of pp145 to binding with SHC, pp145 derived from anti-SHC immunoprecipitates was

transferred from PDGF-stimulated cells to nitrocellulose and treated with tyrosine-specific phosphatases. Dephosphorylation of immobilized pp145 completely eliminated binding to ^{32}P -labeled GST-SHC (Figure 3, Panel A). This effect was prevented by inclusion of the tyrosine phosphatase inhibitor sodium orthovanadate. Conversely, when pp145 from unstimulated cells, which should not bind SHC, was phosphorylated with recombinant PDGF receptor, the pp145 then bound to the PTB domain of the SHC protein SHC. Therefore, binding of SHC to pp145 requires pp145 to be tyrosine phosphorylated. To investigate the mechanism of PTB binding to pp145 further, proteins in cell lysates were separated by SDS-PAGE, transferred to nitrocellulose, and assayed for binding of ^{32}P -labeled GST-SHC to pp145 in the presence of phosphotyrosine. Binding of GST-SHC to pp145 was competitively inhibited by high concentrations of phosphotyrosine, but not by similar concentrations of phosphoserine (Figure 3, Panel B). Phosphotyrosine also inhibited binding of SHC to p180 and p120, which are SH2 domain-dependent interactions. These experiments suggested that binding of the PTB region to pp145 involves recognition of phosphotyrosine, as does SH2 domain binding.

Taken together, these results demonstrate that (i) the PTB domain of SHC specifically binds to pp145 and not to other proteins, (ii) that this interaction requires stimulation of cells by various growth factors, and (iii) that the PTB domain specifically recognizes the tyrosine-phosphorylated form of pp145. This combination of specificities is functionally similar to that of SH2 domains. It was also observed that pp145 could not be effectively dephosphorylated while it was complexed to SHC in immunoprecipitates. This suggested that the PTB domain protected the phosphotyrosine of pp145 from phosphatase action, as do SH2 domains (Birge et al., *J. Biol. Chem.*

267, 10588-10595 (1992)). However, PTB domains clearly have a different structure from SH2 domains. The amino acid sequence of the PTB region of SHC is different from all members of the known SH2 domain family. The only recognizable sequence similarity is a short motif present in the extreme NH₂-terminal end of the PTB domain, GVSYLVR, which is somewhat similar to the consensus sequence for phosphotyrosine binding in SH2 domains, G(S or T)FLVRES (Figure 4) (Mayer et al., *Mol. Cell. Biol.* 12, 609 (1992)). However, mutation of the arginine in this motif (R55 of SHC) to leucine did not affect binding of the PTB domain to pp145, whereas the analogous mutation in SH2 domains eliminates binding to tyrosine phosphorylated targets (Marengere and Pawson *J. Biol. Chem.* 267, 22779-86 (1992); Bibbins et al., *Mol. Cell. Biol.* 13, 7278-87(1993); S. Katzav *Oncogene*, 8, 1757-63 (1993)). The remainder of the PTB domain has little or no sequence similarity with highly conserved residues or motifs present in known SH2 domains, some of which are important for SH2 domain function. The predicted secondary structure of the PTB domain is also different from that of SH2 domains. Accordingly, it is apparent that the structural basis upon which PTB domain phosphotyrosine binding is based is markedly different from that of the known SH2 domains.

B. Identification of the Homologous SCK Protein

Comparison of the DNA sequence of the PTB domain with sequences in computer databases revealed a gene which contained a putative PTB domain. A partial clone of this gene, EST03775, was originally obtained by sequencing expressed sequence tags from human brain cDNA clones (Adams et al., *Nature Genetics* 4,256-267 (1993)), but had not been recognized as a putative signaling molecule. Specifically, only a 305 bp segment had been reported. By screening human placental and HepG2 cDNA libraries with EST03775, a larger partial clone encoding

a protein with a PTB domain and a SH2 domain similar to those of SHC was identified, which is herein referred to as SCK (for ShC-like) (Figure 4). The conserved region of the PTB domain correlated with the PTB domain which had bound to pp145. The identification of a PTB domain in SCK establishes that PTB domains are present in more than one gene. Northern blot analysis demonstrated that the tissue distribution of SCK mRNA is different from that of SHC. SCK mRNA expression is much higher in liver than in other tissues, and is present in brain. SHC mRNA expression is approximately the same in liver as in other tissues, except that it is very low in brain.

These data are consistent with a model in which stimulation of cells with growth factors leads to tyrosine phosphorylation of pp145, which then binds to SHC through its PTB domain. In this way, the PTB domain directs assembly of a signaling complex in the same way as does the SH2 domains of SHC or other signaling proteins. This signaling pathway is also referred to herein as the PTB domain/phosphorylated ligand regulatory system. Thus, pp145, a target of the SHC PTB domain, can also be an important signaling molecule. It has been proposed that SHC links growth factor receptor and non-receptor tyrosine kinases to activation of Ras; one mechanism for this link is formation of a complex of SHC with GRB2, an adapter protein, and with SOS, a guanine nucleotide exchange factor for Ras (Egan et al. Nature, 363,45-51 (1993)). Accordingly, pp145 can also participate in the regulation of Ras signaling by virtue of its association with SHC.

II. - Polypeptides Comprising a PTB Domain

In one aspect, the present invention provides isolated polypeptides which are capable of binding a tyrosine-phosphorylated protein, through a non-SH2 PTB domain. Non-SH2 PTB domains are those protein domains which are capable of specifically binding tyrosine

phosphorylated proteins, but comprise an amino acid sequence which is different from that found in the known SH2 sequences.

The terms "isolated" and "substantially pure" refer, interchangeably, to proteins, polypeptides and nucleic acids which are separated from proteins, or contaminants with which they are naturally associated. A protein or polypeptide is isolated when that protein makes up greater than about 50% of the total protein content of the composition containing that protein, typically, greater than about 60% of the total protein content. More typically, a substantially pure protein will make up from about 75 to about 90% of the total protein. Preferably, the protein will make up greater than about 90%, and more preferably, greater than about 95% of the total protein in the composition.

Isolation and purification of the polypeptides of the present invention can be carried out by methods that are well known in the art. For example, the polypeptides may be purified using readily available chromatographic methods, e.g., ion exchange, hydrophobic interaction, HPLC or affinity chromatography to achieve desired purity. Affinity chromatography can be particularly attractive in allowing the investigator to take advantage of the specific activity of the desired polypeptide, e.g., phosphotyrosine binding.

Exemplary polypeptides will have an amino acid sequence which is substantially homologous to the amino acid sequence of the SHC PTB domain, or phosphotyrosine binding fragments thereof. The phrase "PTB domain" as used herein refers to a polypeptide domain which has an amino acid sequence that is substantially homologous to the amino acid sequence of the SHC non-SH2 phosphotyrosine binding domain. This SHC non-SH2 domain consists of amino acid residues 46 through 232 of the SHC protein amino acid sequence. Also included are sequences which comprise the SCK protein's PTB domain.

By substantially homologous is meant an amino acid sequence which is at least about 50% homologous to the SHC PTB domain, preferably at least about 90% homologous, and more preferably at least about 95% homologous. Examples of preferred polypeptides are those derived from the SHC or SCK proteins, and having the sequence as shown in Figure 4, for the SCK and SHC PTB domains (or Figures 5 and 6, respectively), or phosphotyrosine binding fragments thereof. Thus, included within the present invention are amino acid variants of the SHC and SCK PTB domain sequences, provided those variants retain the ability to bind tyrosine phosphorylated proteins. These variants may include insertions, deletions and substitutions with other amino acids. Glycosylation modifications, either changed, increased amounts or decreased amounts, as well as other sequence modifications are envisioned. Thus the amino acid variants of these polypeptides, e.g., analogs, will generally be substantially equivalent to the amino acid sequence of either the SHC or SCK PTB domain.

Polypeptides of the present invention may also be characterized by their ability to bind antibodies raised against the PTB domains shown in Figure 4. These antibodies recognize polypeptide domains that are homologous to the PTB domain. Homologous domains encompass the family of PTB domains, but do not include other phosphotyrosine binding domains, such as SH2 domains. A variety of immunoassay formats may be used to select antibodies specifically immunoreactive with a particular protein or domain. For example, solid-phase ELISA immunoassays are routinely used to select monoclonal antibodies specifically immunoreactive with a protein. See Harlow and Lane (1988) *Antibodies, A Laboratory Manual*, Cold Spring Harbor Publications, New York, for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity. Antibodies to PTB domains and

polypeptides comprising PTB domains are discussed in greater detail, below.

Phosphotyrosine binding fragments of the above peptides may be identified and prepared by methods well known in the art. For example, selective proteolytic digestion, recombinant deletional methods, or peptide synthesis methods may be employed to identify the specific fragments which are capable of phosphotyrosine binding. See, e.g., Sambrook et al. Typically, such fragments will comprise fewer than about 50 amino acids, more typically, they will comprise fewer than about 20 amino acids, and preferably they will comprise from about 6 to about 15 amino acids.

It may also be desirable to provide the polypeptides of the present invention free of phosphotyrosine binding domains other than the PTB domain. For example, where it is desired to focus only upon PTB domain binding, and the target protein possesses numerous different phosphorylated tyrosine residues. In this case, deletional peptides lacking other phosphotyrosine binding domains, e.g., SH2 domains, may be prepared by recombinant DNA techniques well known in the art.

The polypeptides of the present invention may be used as isolated polypeptides, or may exist as fusion proteins. A "fusion protein" generally refers to a composite protein made up of two separate, heterologous proteins which are normally not fused together as a single protein. Thus, a fusion protein may comprise a fusion of two similar and homologous sequences, provided these sequences are not normally fused together. Fusion proteins will generally be made by either recombinant nucleic acid methods, i.e., as a result of transcription and translation of a gene fusion comprising a segment encoding a polypeptide comprising the PTB domain and a segment which encodes one or more heterologous proteins, or by chemical synthesis methods well known in the art.

These fusion proteins may be prepared to exhibit a combination of properties or activities of the derivative proteins. Typical fusion proteins may include a polypeptide comprising the PTB domain fused to a reporter polypeptide, e.g., a substrate, cofactor, inhibitor, affinity ligand, antibody binding epitope tag, or an enzyme which is capable of being assayed. Because of its ability to recognize and bind specific tyrosine phosphorylation sites in a protein, the PTB domain may act as an affinity ligand to direct the activity of the fused protein directly to tyrosine phosphorylated proteins. In the case of a reporter peptide\PTB domain fusion, this allows the presence and or location of tyrosine phosphorylated proteins which bind the PTB domain to be easily determined. Alternatively, fusion proteins may facilitate isolation and identification of the polypeptides comprising the PTB domain, by providing an easily purifiable hybrid protein, i.e., the polypeptide fused to an affinity ligand, or antibody binding epitope which may then be purified using well known affinity purification methods, or detected. Examples of such affinity ligands and antibody binding epitopes may include, e.g., influenza virus hemagglutinin (IHA) epitope tag, or glutathione-S-transferase. Other typical fusion partners include bacterial β -galactosidase, trpE, protein A, β -lactamase, α -amylase, alcohol dehydrogenase and yeast α -mating factor. See, e.g., Godowski et al., *Science* 241:812-816 (1988).

The polypeptides of the present invention may be prepared by a variety of means, e.g., recombinant or synthetic. In general, techniques for recombinant production of proteins are described, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2nd ed.) Vols. 1-3, Cold Spring Harbor Laboratory, (1989). Techniques for the synthesis of polypeptides are generally described in Merrifield J. *Amer. Chem. Soc.* 85:2149-2456 (1963), Atherton et al., *Solid Phase Peptide*

Synthesis: A Practical Approach, IRL Press, Oxford (1989), and Merrifield, *Science* 232:341-347 (1986).

5 III. Nucleic Acids Encoding Polypeptides Comprising a PTB Domain and Cells Capable of Expressing Same

Also provided in the present invention are isolated nucleic acid sequences that encode polypeptides which comprise a non-SH2 PTB domain. Preferably, such nucleic acid sequences will comprise a segment that is
10 substantially homologous to the nucleotide sequence encoding the SHC or SCK PTB domains. More preferred are those nucleic acid sequences, shown in Figures 5A-C and 6A-C, which comprise the nucleotide sequence encoding the SCK or SHC PTB domain, respectively.

15 Substantial homology in the nucleic acid context means that the segments, or their complementary strands, when compared, are the same when properly aligned, with the appropriate nucleotide insertions or deletions, in at least about 60% of the nucleotides, typically, at least about 70%, more typically, at least
20 about 80%, usually, at least about 90%, and more usually, at least about 95% to 98% of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization
25 conditions to a strand, or its complement, typically using a sequence of at least about 20 contiguous nucleotides derived from the SHC or SCK nucleotide sequence. However, larger segments will usually be preferred, e.g., at least about 30 contiguous
30 nucleotides, more usually about 40 contiguous nucleotides, and preferably more than about 50 contiguous nucleotides. Selective hybridization exists when hybridization occurs which is more selective than total lack of specificity. See, Kanehisa, *Nucleic Acid Res.*
35 12:203-213 (1984).

Nucleic acids of the present invention include RNA, cDNA, genomic DNA, synthetic forms and mixed

polymers, both sense and antisense strands. Furthermore, different alleles of each isoform are also included. The present invention also provides recombinant nucleic acids which are not otherwise naturally occurring. The nucleic acids included in the present invention will typically
5 comprise RNA or DNA or mixed polymers. The DNA compositions will generally include a coding region which encodes a polypeptide comprising an amino acid sequence substantially homologous to the amino acid sequence of
10 the SHC PTB domain. More preferred are those DNA segments comprising a nucleotide sequence as shown in Figures 5 and 6, which encodes the SCK or SHC PTB domains, respectively.

CDNA encoding the polypeptides of the present
15 invention, or fragments thereof, may be readily employed as a probe useful for obtaining genes which encode the PTB containing polypeptides of the present invention. Typical nucleic acid probes may be prepared from the amino acid sequences of the SHC or SCK PTB domain. In
20 particular, probes may be prepared based upon segments of the amino acid sequence which possess relatively low levels of degeneracy, i.e., few or one possible nucleic acid sequences which encode therefor. Suitable synthetic DNA fragments may then be prepared, e.g., by the
25 phosphoramidite method described by Beaucage and Carruthers, *Tetrahedron Letts.* 22:1859-1862 (1981). Alternatively, nucleotide sequences which are relatively conserved among the SHC and SCK PTB domain coding sequences may be used as suitable probes. A double
30 stranded probe may then be obtained by either synthesizing the complementary strand and hybridizing the strands together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence. Such cDNA probes
35 may be used in the design of oligonucleotide probes and primers for screening and cloning such genes, e.g., using well known PCR techniques. Such nucleic acids, or

fragments may comprise part or all of the cDNA sequence that encodes the polypeptides of the present invention. Effective cDNA probes may comprise as few as 15 consecutive nucleotides in the cDNA sequence, but will often comprise longer segments. Further, these probes may further comprise an additional nucleotide sequence, such as a transcriptional primer sequence for cloning, or a detectable group for easy identification and location of complementary sequences.

10 cDNA or genomic libraries of various types may be screened for new alleles or related sequences using the above probes. The choice of cDNA libraries normally corresponds to tissue sources which are abundant in mRNA for the desired polypeptides. Phage libraries are normally preferred, but plasmid libraries may also be used. Clones of a library are spread onto plates, transferred to a substrate for screening, denatured, and probed for the presence of the desired sequences.

The nucleic acids of the present invention may be present in whole cells, cell lysates or in partially pure or substantially pure or isolated form. Such "substantially pure" or "isolated" forms of these nucleic acids generally refer to the nucleic acid separated from contaminants with which it is generally associated, e.g., lipids, proteins and other nucleic acids. The nucleic acids of the present invention will be greater than about 50% pure. Typically, the nucleic acids will be more than about 60% pure, more typically, from about 75% to about 90% pure, and preferably, from about 95% to about 98% pure.

The present invention also includes fragments of the above described nucleic acids. Such fragments will generally comprise a segment of from about 15 to about 150 nucleotides. These fragments can be useful as oligonucleotide probes in the methods of the present invention, or alternatively to encode phosphotyrosine binding polypeptide fragments of the PTB domain as also

described herein. Also provided are substantially similar nucleic acid sequences, allelic variations and natural or induced sequences of the above described nucleic acids. Also included are chemically modified and substituted nucleic acids, e.g., those which incorporate modified nucleotide bases or which incorporate a labelling group.

In addition to comprising a segment which encodes a polypeptide containing a PTB domain, the nucleic acids of the present invention may also comprise a segment encoding a heterologous protein, such that the gene is expressed to produce the two proteins as a fusion protein, as substantially described above.

In addition to their use as probes, the nucleic acids of the present invention may also be used in the preparation of the polypeptides of the present invention, namely those polypeptides comprising the non-SH2 PTB domain.

DNA encoding the polypeptides of the present invention will typically be incorporated into DNA constructs capable of introduction to and expression in an *in vitro* cell culture. Often, the nucleic acids of the present invention may be used to produce a suitable recombinant host cell. Specifically, DNA constructs will be suitable for replication in a unicellular host, such as bacteria, e.g., *E. coli*, but may also be intended for introduction into a cultured mammalian, plant, insect, or other eukaryotic cell lines. DNA constructs prepared for introduction into bacteria or yeast will typically include a replication system recognized by the host, the intended DNA segment encoding the desired polypeptide, transcriptional and translational initiation and termination regulatory sequences operably linked to the polypeptide encoding segment. A DNA segment is operably linked when it is placed into a functional relationship with another DNA segment. For example, a promoter or enhancer is operably linked to a coding sequence if it

stimulates the transcription of the sequence; DNA for a signal sequence is operably linked to DNA encoding a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide.

- 5 Generally, DNA sequences that are operably linked are contiguous, and in the case of a signal sequence both contiguous and in reading phase. However, enhancers need not be contiguous with the coding sequences whose transcription they control. Linking is accomplished by
- 10 ligation at convenient restriction sites or at adapters or linkers inserted in lieu thereof. The selection of an appropriate promoter sequence will generally depend upon the host cell selected for the expression of the DNA segment. Examples of suitable promoter sequences include
- 15 prokaryotic, and eukaryotic promoters well known in the art. See, e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual* (2d ed.), vols. 1-3 Cold Spring Harbor Laboratory (1989). The transcriptional regulatory sequences will typically include a heterologous enhancer
- 20 or promoter which is recognized by the host. The selection of an appropriate promoter will depend upon the host, but promoters such as the trp, lac and phage promoters, tRNA promoters and glycolytic enzyme promoters are known and available. See Sambrook et al., (1989).
- 25 Conveniently available expression vectors which include the replication system and transcriptional and translational regulatory sequences together with the insertion site for the PTB polypeptide encoding segment may be employed. Examples of workable combinations of
- 30 cell lines and expression vectors are described in Sambrook et al., and in Metzger et al., *Nature* 334:31-36 (1988). For example, where an insect host cell is selected as the host cell of choice to express the polypeptide, the cDNA encoding the polypeptides of the
- 35 invention may be cloned into a baculovirus expression vector (pV-IKS). The recombinant baculovirus may then be used to transfect a suitable insect host cell, e.g., Sf9

cells, which may then express the polypeptide. See, e.g., D.K. Morrison et al., *Cell* 58:649-657 (1989), M.D. Summers and G.E. Smith, *A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures*, 5 Texas Agricultural Station, College Station, Texas (1987).

The vectors containing the DNA segments of interest, e.g., those encoding polypeptides comprising the non-SH2 PTB domain, can be transferred into the host 10 cell by well known methods, which may vary depending upon the type of host used. For example, calcium chloride transfection is commonly used for prokaryotic cells, whereas calcium phosphate treatment may be used for other hosts. See, Sambrook et al. The term "transformed cell" 15 as used herein, includes the progeny of originally transformed cells.

IV. Proteins That Bind PTB

Also provided by the present invention are 20 tyrosine phosphorylated proteins which are specifically recognized by the PTB domain. Such proteins are generally produced in response to cell activation, e.g., growth factor activation, and may be identified by their ability to specifically bind the PTB domain. 25 Accordingly, identification and characterization of these proteins can advance the understanding, characterization and manipulation of cell signaling pathways in general.

Specifically provided is an isolated polypeptide having an approximate molecular weight of 145 30 kD. This polypeptide is derived from activated cells. Activated cells refer to mammalian cells, including fibroblasts, myoblasts, B-cells and T-cells of human and nonhuman origin. These cells are generally activated by growth factors, e.g., PDGF, FGF, EGF, insulin and 35 insulin-like growth factors; cytokines and lymphokines, e.g., interleukins; and antibodies and ligands to receptors involved in growth regulation and cell

division. Examples of specific activated cells include, e.g., PDGF activated fibroblasts, such as Balb/c 3T3 cells, FGF activated myoblasts, such as L6 cells, antibody activated B-cells, IL-6 activated hepatoma
5 cells, such as the HepG2 cell line and leukemia inhibitory factor stimulated embryonic stem cells, such as CCE stem cells. This polypeptide is characterized by phosphorylation of one or more tyrosine residues upon activation of a cell, as described above. Further, this
10 protein does not bind an isolated SHC SH2 domain, but will bind polypeptides having the amino acid sequence of the SHC PTB domain. Isolation and purification of these proteins may be carried out by known methods, e.g., ion exchange, HIC, affinity chromatography, HPLC, and the
15 like.

As a specific signal of growth factor activation of cells, this protein provides an ideal target for the non-SH2 PTB binding in the screening methods of the present invention.

20

V. Antibodies

The polypeptides of the present invention, or fragments thereof will be useful in producing antibodies, either polyclonal or monoclonal. These antibodies are
25 produced by immunizing an appropriate vertebrate host, e.g., mouse or rabbit, with the polypeptide or fragment, alone or in conjunction with an adjunct. Usually, two or more immunizations are involved, and a few days following the last injection, the blood or spleen of the host will
30 be harvested.

For production of polyclonal antibodies, an appropriate target immune system is selected, typically a mouse or rabbit, but including goats, sheep, cows, guinea pigs and rats. The substantially purified antigen
35 is presented to the immune system in a fashion determined by methods appropriate for the animal. These and other parameters are well known to immunologists. Typically,

injections are given in the footpads, intramuscularly, intradermally or intraperitoneally. The immunoglobulins produced by the host can be precipitated, isolated and purified by routine methods, including affinity
5 purification.

For monoclonal antibodies, appropriate animals will be selected and the desired immunization protocol followed. After the appropriate period of time, the spleens of these animals are excised and individual
10 spleen cells are fused, typically, to immortalized myeloma cells under appropriate selection conditions. Thereafter, the cells are clonally separated and the supernatants of each clone are tested for the production of an appropriate antibody specific for the desired
15 region of the antigen. Techniques for producing antibodies are well known in the art. See, e.g., Goding et al., *Monoclonal Antibodies: Principles and Practice* (2d ed.) Acad. Press, N.Y., and Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor
20 Laboratory, New York (1988). Other suitable techniques involve the *in vitro* exposure of lymphocytes to the antigenic polypeptides or alternatively, to selection of libraries of antibodies in phage or similar vectors. Huse et al., Generation of Large Combinatorial Library of
25 the Immunoglobulin Repertoire in Phage Lambda, *Science* 246:1275-1281 (1989). Monoclonal antibodies with affinities of 10^8 liters/mole, preferably 10^9 to 10^{10} or stronger, will be produced by these methods.

The antibodies generated can be used for a
30 number of purposes, e.g., as probes in immunoassays, for inhibiting PTB binding to its target tyrosine phosphorylated proteins, in diagnostics or therapeutics, or in research to further elucidate the functioning of the signaling pathways in activation of cells by growth
35 factors, hormones, cytokines or the like.

The antibodies of the present invention can be used with or without modification. Frequently, the

antibodies will be labelled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. Such labels include those that are well known in the art, such as those as described previously for the polypeptides of the invention.

Preferred antibodies are those which specifically recognize polypeptides which comprise a phosphotyrosine binding domain which is non-SH2. More preferred are those antibodies which bind to polypeptides having an amino acid sequence substantially homologous to the amino acid sequence of SHC PTB domain. Still more preferred are those antibodies which bind to polypeptides comprising the amino acid sequence of the SHC or SCK PTB domains.

15

VI. Methods for Use

A. Diagnostics and Screening

As noted above, the polypeptides comprising the PTB domain may be particularly useful as affinity ligands capable of binding tyrosine phosphorylated proteins. Further, tyrosine phosphorylation of proteins is a common signal in cellular functioning. Accordingly, the polypeptides of the present invention may find a variety of uses in research, as well as diagnostic and therapeutic applications.

For example, the polypeptides comprising the PTB domain may generally be useful in methods for identifying tyrosine phosphorylated proteins. Such methods may allow for the identification of proteins involved in signaling pathways, such as cell activation following the binding of a ligand to a cell surface receptor. Specifically, these methods are useful in identifying downstream signals following growth factor, hormone, antibody and cytokine activation of cells.

In one aspect, one may use the polypeptides of the present invention to detect whether a protein is capable of binding the PTB domain, that is, whether the

protein is tyrosine phosphorylated in the first instance. Detection of tyrosine phosphorylated proteins using the polypeptides of the present invention may be accomplished by a number of means. For example, in some instances, it
5 may be useful to immobilize the protein to be tested upon a solid support, e.g., a microtiter well, or nitrocellulose membrane. After blocking of remaining groups on the support, the protein to be tested may be exposed to an appropriate amount of the labelled
10 polypeptide containing the PTB domain, as described herein. Detection of the label bound to the test protein indicates that the protein is tyrosine phosphorylated. As a specific example, following SDS-PAGE, the gel may be electroblotted onto an appropriate solid support, e.g.,
15 a nitrocellulose or PVDF membrane. Remaining unbound regions of the membrane may then be blocked with an appropriate inert protein, e.g., bovine serum albumin. Following buffer rinses, the blot is then contacted with a polypeptide comprising a PTB domain and a detectable
20 group, e.g., a radiolabel or enzyme. Radiographs of the blot may be compared to simultaneously run, stained SDS-PAGE gels, and the radiolabel bound proteins may be identified. Specific methods for SDS-PAGE, electroblotting, and radiograph exposures are very well
25 known in the art.

Alternatively, the methods of the present invention may be applied to detect the presence, absence, increase or decrease in the level of tyrosine phosphorylated protein *in vitro* or *in vivo*. The ability
30 to detect signals of cellular functioning allows for the screening of compounds which affect that functioning. For example, by detecting the increase or decrease in the level of tyrosine phosphorylated proteins in response to contact with a particular compound, one can determine
35 whether the compound is an agonist or antagonist of a cellular function which results in that tyrosine phosphorylation of proteins *in vivo*.

To assay for compounds that act as agonists or antagonists of functions which result in tyrosine phosphorylation, cells are exposed to known agonists, known antagonists, and/or test compounds which may be, or
5 may contain, agonists or antagonists. An agonist, antagonist, or test compound may be a chemical compound, a mixture of chemical compounds, a biological macromolecule, or an extract made from biological materials such as bacteria, plants, fungi, or animal
10 cells or tissues. Test compounds are evaluated for potential activity as agonists or antagonists of functions which result in tyrosine phosphorylation by inclusion in screening assays described herein. An "agonist" will enhance the level of tyrosine
15 phosphorylated proteins in an activated cell, while an "antagonist" will diminish the level of tyrosine phosphorylated proteins. The terms "agonist" and "antagonist", as used herein, do not imply a particular mechanism of function.

20 For many of the methods of the present invention, the polypeptides and nucleic acids of the invention may be covalently attached or linked to a detectable group to facilitate screening and detection. Useful detectable groups, or labels, are generally well
25 known in the art. For example, a detectable group may be a radiolabel, such as, ^{125}I , ^{32}P or ^{35}S , or a fluorescent or chemiluminescent group. Alternatively, the detectable group may be a substrate, cofactor, inhibitor, affinity ligand, antibody binding epitope tag, or an enzyme which
30 is capable of being assayed. Suitable enzymes include, e.g., horseradish peroxidase, luciferase, or another readily assayable enzymes. These enzyme groups may be attached to the PTB containing polypeptide by chemical means or expressed as a fusion protein, as already
35 described.

In a specific aspect, a method is provided for determining whether a compound is an agonist or

antagonist of a cellular activation signaling pathway. For these embodiments, the test compound to be screened may be incubated with activatable cells, which are characterized by their activation of tyrosine kinases, and thus, tyrosine phosphorylation of proteins, upon activation. Specific examples of these cells include PDGF activated fibroblasts, FGF activated myoblasts, such as L6 cells, antibody activated B-cells, activated T-cells, IL-6 activated hepatoma cells, such as the HepG2 cell line and leukemia inhibitory factor stimulated embryonic stem cells, such as CCE stem cells.

Following exposure to the activating agent, i.e., a growth factor, the cells are lysed, and the polypeptides of the present invention comprising the PTB domain may be used to assay the cell lysate for an increase or decrease in the level of tyrosine phosphorylated proteins in the cell in response to activation in the presence of the test compound. Preferably, the lysate may be assayed for the presence of pp145. Methods for preparation of a cell lysate are well known in the art (see, e.g., *Methods in Enzymology* Vol. 198, *supra*). Typically, cells are homogenized in the presence of buffers (e.g., Tris-HCl, HEPES), nonionic detergents (e.g., Tween-20; Triton X-100), and protease inhibitors (e.g., PMSF, aprotinin, leupeptin). Other inhibitors, such as phosphatase inhibitors (e.g., orthovanadate), may also be desirable. Typically conditions are chosen that are nondenaturing to the cellular proteins of interest. A preferred method for preparation of a cell lysate is by addition of lysis buffer (20mM Tris-HCl, pH 7.3, 150 mM NaCl, 1% Triton X-100, 1mM PMSF, 1mM sodium orthovanadate, 10 μ g/ml aprotinin and 10 μ g/ml leupeptin) followed by cell disruption (e.g., by shaking or scraping). Usually, when preparing a cell lysate the insoluble matter in the cell lysate is removed by centrifugation (e.g., 10,000 xg for 15 min.) and the clarified supernatant is recovered.

Where exposure to the compound results in an increase or decrease in the level of tyrosine phosphorylated proteins in response to cell activation, when compared to an appropriate control, it is indicative that the compound
5 may be an agonist or antagonist of a cell activation signaling pathway, respectively.

The amount or concentration of agonist/antagonist added will, when known, vary depending on the compound, but will generally range from about 10pM
10 to 100 μ M. Typically, a variety of concentrations will be used. In the case of uncharacterized test compounds it may not be possible, and it is not necessary, to determine the concentration of agonist/antagonist.

It will also be desirable to include various
15 experimental controls in the assay. Examples of appropriate controls include negative controls and positive controls. In testing for agonist activity, negative controls can include incubation of cells with inert compounds (i.e., compounds known not to have
20 agonist activity) or in the absence of added compounds. Positive controls can include incubation of cells with compounds known to have agonist activity (e.g., the natural ligand). Logically similar (though complementary) controls can be included in assays for antagonist
25 activity, as will be apparent to one of ordinary skill in the art of biology, as will be various additional controls. The description of controls is meant to be illustrative and in no way limiting.

More narrowly, the polypeptides of the present
30 invention can be used as a model *in vitro* system for determining whether a compound is an agonist or antagonist of the binding of the PTB domain to its phosphorylated ligand. "Phosphorylated ligand" refers to a protein or polypeptide which is capable of interacting
35 with the PTB domain to form a complex, e.g., tyrosine phosphorylated proteins such as ppl45, or fragments thereof. These methods comprise providing a polypeptide

comprising the PTB domain, and the phosphorylated ligand capable of interacting with the PTB domain, e.g., tyrosine phosphorylated proteins, such as pp145, to form a complex. The complex may then be incubated with a test compound. Binding between the PTB domain and the ligand may then be determined. An increase or decrease in the level of binding between the phosphorylated ligand and the polypeptide of the invention (comprising the PTB domain) in response to a particular compound would indicate that the compound is an agonist or antagonist of that binding, respectively. In some cases, it may be desirable to preincubate the phosphorylated ligand with the test compound, prior to introduction of the polypeptide comprising the PTB domain. The duration and conditions of preincubation will generally vary depending upon the compound being tested. Generally, this preincubation may be from about 5 minutes to about 1 hour. Further, the pH and temperature of the preincubation will generally correspond to the pH and temperature which are most effective for PTB domain binding to the protein. Accordingly, these conditions will likely reflect the conditions normal to the particular cell-line from which the PTB domain was derived.

It may also be desirable to provide the tyrosine phosphorylated ligand or polypeptide comprising the PTB domain immobilized upon a solid support, to facilitate screening of test compounds. Examples of suitable solid supports include agarose, cellulose, dextran, Sephadex, Sepharose, carboxymethyl cellulose, polystyrene, filter paper, nitrocellulose, ion exchange resins, plastic films, glass beads, polyaminemethylvinylether maleic acid copolymer, amino acid copolymer, ethylene-maleic acid copolymer, nylon, silk, etc. The support may be in the form of, e.g., a test tube, microtiter plate, beads, test strips, or the like. The reaction of the polypeptide or phosphorylated

ligand with the particular solid support may be carried out by methods well known in the art.

In the case of a microtiter plate, the test compound may be added to the well of the microtiter plate to preincubate with the tyrosine phosphorylated protein. The polypeptide comprising the PTB domain may then be added to the microtiter well, and binding of the PTB domain to the protein may be assessed, e.g., by detection of detectable groups. The level of binding may then be compared to suitable positive and negative controls. Alternatively, by providing the polypeptide containing the PTB domain, and/or the phosphorylated ligand in known concentrations, one can assay for free, or unbound PTB domain and/or phosphorylated ligand, and by negative implication, determine the level of PTB domain/phosphorylated ligand complex which is formed.

Additionally, as an affinity ligand, the polypeptides comprising the PTB domain may also be useful in the purification of tyrosine phosphorylated proteins from a mixture of different proteins. Affinity purification of tyrosine phosphorylated proteins may be carried out using general affinity purification methods well known in the art. For example, the polypeptide of the present invention may be attached to a suitable solid support. Suitable solid supports include those generally well known in the art, e.g., cellulose, agarose, polystyrene, divinylbenzene and the like. Many suitable solid supports are commercially available from, e.g., Sigma Chemical Co., St Louis, Missouri, or Pharmacia, Uppsala, Sweden, and come prepared for immediate coupling of affinity ligands.

The mixture of proteins may be contacted with the polypeptide bound to the solid support, such that the polypeptide selectively binds the tyrosine phosphorylated proteins within the mixture of proteins. The bound protein can then be washed to eliminate unbound proteins. Finally, substantially pure tyrosine phosphorylated

protein may be eluted from the solid support by generally known elution protocols, e.g., washing with an excess of phosphotyrosine, which will compete with the binding of PTB to its target protein.

5 Alternatively, the non-SH2 PTB domain polypeptides of the present invention may be useful in modelling small molecules which interfere with PTB binding *in vivo*. In particular, the structure of the PTB domain, and more specifically, the actual phosphotyrosine
10 binding site, from the known amino acid sequence and the 3-dimensional structure, which may be determined by x-ray crystallographic methods known in the art, may be applied in generating synthetic analogs and mimics of the particular PTB domain and, more specifically, the precise
15 phosphotyrosine binding site. Synthetic elements may be pieced together based upon their analogy to the structural and chemical aspects of the PTB domain. Such mimics and analogs may be used in blocking or inhibiting specific aspects of the cell signaling pathways, e.g.,
20 growth factor activation, and may thus be useful as therapeutic treatments according to the methods described herein.

B. Therapeutics

25 In addition to the above described uses, the polypeptides and nucleic acids of the present invention may also be used in therapeutic applications for the treatment of human or non-human mammalian patients.

 As a specific example, the polypeptides of the
30 present invention may be used to inhibit or block the growth factor dependent activation or stimulation of cells, or more specifically, inhibit or block growth factor initiated mitogenesis. These methods may generally be used in the treatment of a variety of
35 proliferative cell disorders, or in screening compounds effective for such treatment. "Proliferative cell disorder" refers generally to disorders which are

characterized by excessive stimulation or activation of the mitogenic signaling pathways resulting in excessive or abnormal cell growth and/or differentiation. Specific disorders include, e.g., atherosclerosis, inflammatory joint diseases, psoriasis, restinosis following angioplasty, and cancer. The methods and compositions of the present invention may be particularly useful in the case of cancers where there are deregulated tyrosine kinases, such as thyroid, breast carcinoma, stomach cancer and neuroblastoma. Alternatively, the methods and compositions may be useful as prophylactic treatment, or in screening for compounds effective in prophylactic treatments. Such prophylactic treatments will generally be administered to inhibit or block "normal" cell proliferation, for example, in immunosuppression to prevent graft rejection, and to alleviate allergic responses involving mast cell activation.

Along this line, it can be appreciated that phosphotyrosine binding analogs of the polypeptides of the present invention may also be effective in blocking growth factor dependent activation. Specifically, synthetic analogs to the phosphotyrosine binding site, as described previously, of the polypeptides of the present invention may also be applied in the treatments described herein.

The quantities of reagents necessary for effective therapy, also referred to herein as an "effective amount," or "therapeutically effective amount," will depend upon many different factors, including means of administration, target site, physiological state of the patient and other medicants administered. Thus, treatment doses will need to be titrated to optimize safety and efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further

predictive indication of human dosage. Generally, therapeutically effective amounts of the PTB domain containing polypeptides of the present invention will be from about 0.0001 to about 100 mg/kg, and more usually, from about 0.001 to about 0.1 mg/kg of the host's body weight. Various considerations are described, e.g., in Gilman et al., (Eds.), *Goodman and Gilman's: The Pharmacological Basis of Therapeutics*, (8th ed. 1990), Pergamon Press, and *Remington's Pharmaceutical Sciences* (7th ed. 1985) Mack Publishing Co., Easton, Penn. Methods of administration, also discussed in the above references, include, e.g., oral, intravenous, intraperitoneal or intramuscular administration, and local administration, including topical, transdermal diffusion and aerosol administration, for therapeutic, and/or prophylactic treatment. The active agent, i.e., the PTB domain containing polypeptide, will generally be administered in a composition additionally comprising a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers will include water, saline, buffers and other compounds described in, e.g., the Merck Index, Merck and Co., Rahway, New Jersey.

Constituents of pharmaceutical compositions, in addition to the active agents, include those generally known in the art for the various administration methods used. For example, oral forms generally include powders, tablets, pills, capsules, lozenges and liquids. Similarly, intravenous, intraperitoneal or intramuscular formulations will generally be dissolved or suspended in a pharmaceutically acceptable carrier, e.g., water, buffered water, saline and the like. Additionally, these compositions may include additional constituents which may be required to approximate physiological conditions, such as pH adjusting and buffering agents, tonicity adjusting agents, wetting agents and the like. For solid compositions, conventional nontoxic solid carriers may be used which include, e.g., pharmaceutical grades of

mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate and the like.

Administration may also be carried out by way
5 of a controlled release composition or device, whereby a slow release of the active ingredient allows continuous administration over a longer period of time.

Additionally, because tyrosine phosphorylation, and consequently phosphotyrosine binding, plays an
10 important role in cell signaling pathways, the present invention can provide an exogenous regulatory mechanism in the treatment of these disorders. In particular, the treatment of a particular disorder may comprise gene therapy techniques involving the mutation or
15 dysregulation of a particular PTB domain/phosphorylated ligand regulatory scheme. For example, in the treatment of diseases associated with excessive activity of this regulatory scheme, the methods of the present invention may be applied in reducing that activity. Such a
20 reduction of this activity may involve mutation of genes encoding PTB domains, and/or their phosphorylated ligands. Alternatively, gene therapy techniques may involve the introduction into afflicted cells, of genes which encode a PTB domain. This exogenously introduced
25 PTB domain may compete with the overactive or over expressed PTB containing proteins, thus down regulating the regulatory schemes with which they are associated.

Strategies for gene therapy are reviewed in Friedmann, *Science* 244:1275 (9189). Genetic constructs
30 encoding the PTB domain or functional derivative of that domain, can be used in these gene therapy techniques. Delivery of the genetic construct of interest, i.e., the nucleic acid encoding a non-SH2 PTB domain polypeptide, may be accomplished in vivo by administering the therapy
35 vector to an individual patient, typically by systemic administration (e.g., intravenous, intraperitoneal, intramuscular, subdermal, or intracranial

administration). Alternatively, the vector may be used to deliver nucleic acids to cells *ex vivo*, such as cells explanted from an individual patient or universal donor hematopoietic stem cells, neurons, etc, e.g., by
5 transfection of the cells with nucleic acids of interest cloned into retroviruses. Following transfection, the cells are reimplanted into the patient, usually after selection for cells which have incorporated the nucleic acid. The infusion into the patient of transfected cells
10 can replace cells which are dysfunctional for the particular regulatory scheme which results in the disorder being treated.

The present invention is further illustrated by the following examples. These examples are merely to
15 illustrate aspects of the present invention and are not intended as limitations of this invention.

EXAMPLES

- A. In Vivo Association of SHC with PP145 Proteins
20 Balb/c 3T3 cells, or L6 myoblasts expressing the human FGF receptor 1 [D.E. Johnson, P.L. Lee, J. Lu, L.T. Williams *Mol. Cell. Biol.* 10, 4728. (1990)], were grown to confluence in Dulbecco's modified Eagle medium containing bovine calf serum (10%), antibiotics, and for
25 L6 cells, 800 μ g/ml G418. Cells were stimulated at 37°C for 10 min with either BB PDGF (2 nM) or basic FGF (25 ng/ml) and lysed at 4°C in 1 ml/ 10^6 cells of lysis buffer [20 mM Tris-HCL (pH 8.0), 137 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM sodium orthovanadate, 100 mM NaF, 10
30 mM Na-pyrophosphate, 1 mM EGTA, 1.5 mM $MgCl_2$, 1 mM PMSF, 0.15 units/ml aprotinin and 20 μ M leupeptin]. Lysates were cleared by centrifugation at 13,000 g for 10 min at 4°C. Immunoprecipitations were done as described in W.M. Kavanaugh, A. Klippel, J.A. Escobedo, L.T. Williams *Mol.*
35 *Cell. Biol.* 12, 3415 (1992). SHC antibodies were raised against bacterially-expressed GST-SHC SH2 domain fusion

protein essentially as described in Pelicci et al. Cell 70, 93-104 (1992).

Proteins having 52kD, 66 kD and 145 kD were immunoprecipitated with anti-SHC. The 52 and 66-kD proteins correspond with the 52-kD SHC protein and 66-kD SHC related protein seen in fibroblasts (shown by the black arrows in Figure 1; the pp145 proteins are indicated by the open arrows).

10 B. SHC Binding to pp145 Proteins

Proteins from PDGF-stimulated cell lysates and from anti-SHC immunoprecipitates from quiescent (-) or PDGF-stimulated (+) Balb/c 3T3 cells were analyzed by SDS-PAGE and transferred to nitrocellulose. The filters were incubated with ³²P-labeled GST-SHC fusion proteins as probes.

A full-length human cDNA clone of SHC was obtained from polymerase chain reaction (PCR) of K562 or SK cell cDNA on the basis of the published sequence. Sequencing revealed two differences from the published sequence: a silent T to C transition at position 1276, and an insertion of 3 bases (GCA) which resulted in an in-frame alanine insertion corresponding to amino acid 308. Because all clones contained the same changes, this likely represents a polymorphism. The cDNA was cloned into a baculovirus expression vector (pV-IKS) which contained, from 5' to 3': the glutathione S-transferase gene, the influenza virus hemagglutinin (IHA) epitope tag, a recognition sequence for cAMP-dependent protein kinase, and the SHC gene. Proteins were expressed by infecting Sf9 insect cells with recombinant baculovirus as described in D.K. Morrison et al. Cell 58, 649-657 (1989), M.D. Summers and G.E. Smith, *A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures*. (Texas Agricultural Station, College Station, Texas, 1987). Deletions of SHC indicated in Fig. 2C were obtained by PCR and cloned into the same

vector. GST-SHC fusion proteins were purified by binding to glutathione-agarose (K. Guan and J.E. Dixon *Anal. Biochem.* 192, 262-267(1991)). The bound proteins were then incubated in 20 mM Tris-HCL (pH 7.5), 1 mM DTT, 100 mM NaCl, 12 mM MgCl₂, 0.5 mCi of gamma-³²P-ATP (6000 Ci/mmol), and 250 units of cAMP-dependent protein kinase catalytic subunit from bovine heart for 1 hour at room temperature. The agarose beads were then washed extensively and eluted with 10 mM glutathione. The specific activity of all preparations was typically > 1 x 10⁷ cpm/μg. SDS-PAGE analysis demonstrated a single band at the predicted sizes for the GST-SHC fusion proteins by either Coomassie staining or autoradiography. Immunoprecipitates or portions of cell lysates containing equal amounts of total protein were separated by SDS-PAGE and transferred to nitrocellulose. The filters were blocked for 2 hours at 4°C in nonfat dry milk (5%) in hybridization buffer [20 mM HEPES (pH 7.7), 75 mM KCl, 0.1 mM EDTA, 2.5 mM MgCl₂, 1 mM DTT, and 0.05% Triton X-100]. The filters were then incubated overnight at 4°C in hybridization buffer containing milk (1%) and 2.5 x 10⁵ cpm/ml of ³²P-labeled GST-SHC fusion protein as a probe. The filters were then washed three times in hybridization buffer with milk (1%), dried, and exposed to X-ray film with an intensifying screen for 6 to 36 hours at -70°C.

The results of blotting pp145 protein from lysates or anti-SHC immunoprecipitates from PDGF-stimulated fibroblasts blotted, with ³²P-labeled SHC, SHC in which the SH2 domain had been deleted (SHCΔSH2, residues 1 to 377), and isolated SHC SH2 domain (residues 378 to 473), are shown as the left, middle and right panels of Figure 2(B), respectively.

Deletion of the SHC SH2 domain eliminated binding to the 180 and 120 kD proteins from cell lysates but did not affect binding of SHC to the 145 kD proteins. The isolated SHC SH2 region bound to both the 120 and 180 kD proteins but did not bind to the 145 kD proteins.

Further deletional analysis led to the 186 amino acid fragment of SHC (residues 46-232, the PTB domain) which bound the 145 kD protein without binding the 120 or 180 kD proteins.

5 The binding of the PTB domain to the 145 kD protein in solution was further investigated. GST-SHCASH2 protein containing the influenza virus hemagglutinin (IHA) epitope was incubated with lysate of activated B cells and then purified by immunoaffinity
10 chromatography using monoclonal antibody to IHA.

 Lysates were prepared in hybridization buffer from 2.5×10^7 Bal 17 cells stimulated by cross-linking the B cell antigen receptor as described in T.M. Saxton et al., *J. Immunol.* 153, 623-36 (1994). The lysate was
15 incubated with approximately 250 ng of GST-SHCASH2 protein containing the IHA epitope tag for 1 hour at 4°C. The mixture was then subjected to immunoaffinity chromatography using a monoclonal antibody to IHA covalently attached or linked to agarose beads. The
20 column was washed with 50 column volumes of hybridization buffer and eluted with 2% SDS. Proteins in equal fractions of the starting mixture, column flow-through and SDS eluate were separated by SDS-PAGE, transferred to nitrocellulose and blotted with 32 P-labeled PTB domain
25 protein probe. In B cells, pp145 is seen as a doublet. The starting material, column flow-through and SDS eluates were analyzed by blotting with 32 P-labeled PTB domain probe as described above.

30 C. Phosphotyrosine Involvement in SHC-pp145 Binding

 Proteins in anti-SHC immunoprecipitates from PDGF-stimulated fibroblasts were immobilized on nitrocellulose and treated with tyrosine-specific phosphatases ("PTPase") in the presence or absence of the
35 PTPase inhibitor sodium orthovanadate.

 Anti-SHC immunoprecipitates from PDGF-stimulated fibroblasts immobilized on nitrocellulose

filters were incubated in 25 mM imidazole, pH 7.0, 50 mM NaCl, 2.5 mM EDTA, 5 mM DTT, 100 µg/ml acetylated bovine serum albumin and 5 units each of LAR and T cell tyrosine-specific phosphatases for 60 min at 30°C. An
5 equivalent sample was treated identically except that 5 mM sodium orthovanadate was included. The filters were then washed extensively and blotted with ³²P-GST-SHC as above, except that the hybridization buffer included 1 mM vanadate. The filters were then blotted with ³²P-labeled
10 GST-SHC or immunoblotted with antibody to phosphotyrosine. The results are shown in figure 3(A), top and bottom, respectively.

Lysates from PDGF-stimulated cells were blotted with ³²P-labeled GST-SHC in the presence of the
15 concentrations of phosphotyrosine or phosphoserine indicated in Figure 3.

While the foregoing invention has been described in some detail for purposes of clarity and understanding, it will be clear to one skilled in the art
20 from a reading of this disclosure that various changes in form and detail can be made without departing from the true scope of the invention. All publications and patent documents cited in this application are incorporated by reference in their entirety for all purposes to the same
25 extent as if each individual publication or patent document were so individually denoted.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT: THE REGENTS OF THE UNIVERSITY OF
CALIFORNIA

(ii) TITLE OF INVENTION: Novel Protein Domain Which Binds
Tyrosine Phosphorylated Proteins

(iii) NUMBER OF SEQUENCES: 9

(iv) CORRESPONDENCE ADDRESS:

(A) ADDRESSEE: Robbins, Berliner & Carson
(B) STREET: 201 N. Figueroa Street, 5th Floor
(C) CITY: Los Angeles
(D) STATE: California
(E) COUNTRY: USA
(F) ZIP: 90012-2628

(v) COMPUTER READABLE FORM:

(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.25

(vi) CURRENT APPLICATION DATA:

(A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:

(vii) ATTORNEY/AGENT INFORMATION:

(A) NAME: Berliner, Robert
(B) REGISTRATION NUMBER: 20,121
(C) REFERENCE/DOCKET NUMBER: 5555-348

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: 213-977-1001
(B) TELEFAX: 213-977-1003

(2) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 428 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Pro Gly Ser Gly Asp Ala Ala Ala Ala Glu Trp Ile Arg Lys Gly
 1           5           10           15
Ser Phe Ile His Lys Pro Ala His Gly Trp Leu His Pro Asp Ala Arg
          20           25           30
Val Leu Gly Pro Gly Val Ser Tyr Val Val Arg Tyr Met Gly Cys Ile
          35           40           45
Glu Val Leu Arg Ser Met Arg Ser Leu Asp Phe Asn Thr Arg Thr Gln
          50           55           60
Val Thr Arg Glu Ala Ile Asn Arg Ile His Glu Ala Val Pro Gly Val
          65           70           75           80
Arg Gly Ser Trp Lys Lys Lys Ala Pro Asn Lys Ala Leu Ala Ser Val
          85           90           95

```

44

Leu Gly Lys Ser Asn Leu Arg Phe Ala Gly Met Ser Ile Ser Ile His
 100 105 110
 Ile Ser Thr Asp Gly Leu Ser Leu Ser Val Pro Ala Thr Arg Gln Val
 115 120 125
 Ile Ala Asn His His Met Pro Ser Ile Ser Phe Ala Ser Gly Gly Asp
 130 135 140
 Thr Asp Met Thr Asp Tyr Val Ala Tyr Val Ala Lys Asp Pro Ile Asn
 145 150 155 160
 Gln Arg Ala Cys His Ile Leu Glu Cys Cys Glu Gly Leu Ala Gln Ser
 165 170 175
 Ile Ile Ser Thr Val Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr
 180 185 190
 Leu His Ser Pro Pro Lys Val Ala Leu Pro Pro Glu Arg Leu Ala Gly
 195 200 205
 Pro Glu Glu Ser Ala Trp Gly Asp Glu Glu Asp Ser Leu Glu His Asn
 210 215 220
 Tyr Tyr Asn Ser Ile Pro Gly Lys Glu Pro Pro Leu Gly Gly Leu Val
 225 230 235 240
 Asp Ser Arg Leu Ala Leu Thr Gln Pro Cys Ala Leu Thr Ala Leu Asp
 245 250 255
 Gln Gly Pro Ser Pro Ser Leu Arg Asp Ala Cys Ser Leu Pro Trp Asp
 260 265 270
 Val Gly Ser Thr Gly Thr Ala Pro Pro Gly Asp Gly Tyr Val Gln Ala
 275 280 285
 Asp Ala Arg Gly Pro Pro Asp His Glu Glu His Leu Tyr Val Asn Thr
 290 295 300
 Gln Gly Leu Asp Ala Pro Glu Pro Glu Asp Ser Pro Lys Lys Asp Leu
 305 310 315 320
 Phe Asp Met Arg Pro Phe Glu Asp Ala Leu Lys Leu His Glu Cys Ser
 325 330 335
 Val Ala Ala Gly Val Thr Ala Ala Pro Leu Pro Leu Glu Asp Gln Trp
 340 345 350
 Pro Ser Pro Pro Thr Arg Arg Ala Pro Val Ala Pro Thr Glu Glu Gln
 355 360 365
 Leu Arg Gln Glu Pro Trp Tyr His Gly Arg Met Ser Arg Arg Ala Ala
 370 375 380
 Glu Arg Met Leu Arg Ala Asp Gly Asp Phe Leu Val Arg Asp Ser Val
 385 390 395 400
 Thr Asn Pro Gly Gln Tyr Val Leu Thr Gly Met His Ala Gly Gln Pro
 405 410 415
 Lys His Leu Leu Leu Val Asp Pro Glu Gly Val Val
 420 425

(2) INFORMATION FOR SEQ ID NO:2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 184 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: protein

45

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Leu Gly Pro Gly Val Ser Tyr Val Val Arg Tyr Met Gly Cys Ile Glu
 1 5 10 15
 Val Leu Arg Ser Met Arg Ser Leu Asp Phe Asn Thr Arg Thr Gln Val
 20 25 30
 Thr Arg Glu Ala Ile Asn Arg Ile His Glu Ala Val Pro Gly Val Arg
 35 40 45
 Gly Ser Trp Lys Lys Lys Ala Pro Asn Lys Ala Leu Ala Ser Val Leu
 50 55 60
 Gly Lys Ser Asn Leu Arg Phe Ala Gly Met Ser Ile Ser Ile His Ile
 65 70 75 80
 Ser Thr Asp Gly Leu Ser Leu Ser Val Pro Ala Thr Arg Gln Val Leu
 85 90 95
 Ala Asn His His Met Pro Ser Ile Ser Phe Ala Ser Gly Gly Asp Thr
 100 105 110
 Asp Met Thr Asp Tyr Val Ala Tyr Val Ala Lys Asp Pro Ile Asn Gln
 115 120 125
 Arg Ala Cys His Ile Leu Glu Cys Cys Glu Gly Leu Ala Gln Ser Ile
 130 135 140
 Ile Ser Thr Val Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr Leu
 145 150 155 160
 His Ser Pro Pro Lys Val Ala Leu Pro Pro Glu Arg Leu Ala Gly Pro
 165 170 175
 Glu Glu Ser Ala Trp Gly Asp Glu
 180

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 423 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

Arg Thr Arg Val Glu Gly Gly Gln Leu Gly Gly Glu Glu Trp Thr Arg
 1 5 10 15
 His Gly Ser Phe Val Asn Lys Pro Thr Arg Gly Trp Leu His Pro Asn
 20 25 30
 Asp Lys Val Met Gly Pro Gly Val Ser Tyr Leu Val Arg Tyr Met Gly
 35 40 45
 Cys Val Glu Val Leu Gln Ser Met Arg Ala Leu Asp Phe Asn Thr Arg
 50 55 60
 Thr Gln Val Thr Arg Glu Ala Ile Ser Leu Val Cys Glu Ala Val Pro
 65 70 75 80
 Gly Ala Lys Gly Ala Thr Arg Arg Arg Lys Pro Cys Ser Arg Pro Leu
 85 90 95
 Ser Ser Ile Leu Gly Arg Ser Asn Leu Lys Phe Ala Gly Met Pro Ile
 100 105 110

46

Thr Leu Thr Val Ser Thr Ser Ser Leu Asn Leu Met Ala Ala Asp Cys
 115 120 125
 Lys Gln Ile Ile Ala Asn His His Met Gln Ser Ile Ser Phe Ala Ser
 130 135 140
 Gly Gly Asp Pro Asp Thr Ala Glu Tyr Val Ala Tyr Val Ala Lys Asp
 145 150 155 160
 Pro Val Asn Gln Arg Ala Cys His Ile Leu Glu Cys Pro Glu Gly Leu
 165 170 175
 Ala Gln Asp Val Ile Ser Thr Ile Gly Gln Ala Phe Glu Leu Arg Phe
 180 185 190
 Lys Gln Tyr Leu Arg Asn Pro Pro Lys Leu Val Thr Pro His Asp Arg
 195 200 205
 Met Ala Gly Phe Asp Gly Ser Ala Trp Asp Glu Glu Glu Glu Pro
 210 215 220
 Pro Asp His Gln Tyr Tyr Asn Asp Phe Pro Gly Lys Glu Pro Pro Leu
 225 230 235 240
 Gly Gly Val Val Asp Met Arg Leu Arg Glu Gly Ala Ala Pro Gly Ala
 245 250 255
 Ala Arg Pro Thr Ala Pro Asn Ala Gln Thr Pro Ser His Leu Gly Ala
 260 265 270
 Thr Leu Pro Val Gly Gln Pro Val Gly Gly Asp Pro Glu Val Arg Lys
 275 280 285
 Gln Met Pro Pro Pro Pro Pro Cys Pro Ala Gly Arg Glu Leu Phe Asp
 290 295 300
 Asp Pro Ser Tyr Val Asn Val Gln Asn Leu Asp Lys Ala Arg Gln Ala
 305 310 315 320
 Val Gly Gly Ala Gly Pro Pro Asn Pro Ala Ile Asn Gly Ser Ala Pro
 325 330 335
 Arg Asp Leu Phe Asp Met Lys Pro Phe Glu Asp Ala Leu Arg Val Pro
 340 345 350
 Pro Pro Pro Gln Ser Val Ser Met Ala Glu Gln Leu Arg Gly Glu Pro
 355 360 365
 Trp Phe His Gly Lys Leu Ser Arg Arg Glu Ala Glu Ala Leu Leu Gln
 370 375 380
 Leu Asn Gly Asp Phe Leu Val Arg Glu Ser Thr Thr Thr Pro Gly Gln
 385 390 395 400
 Tyr Val Leu Thr Gly Leu Gln Ser Gly Gln Pro Lys His Leu Leu Leu
 405 410 415
 Val Asp Pro Glu Gly Val Val
 420

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 186 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Gly Pro Gly Val Ser Tyr Leu Val Arg Tyr Met Gly Cys Val Glu
 1 5 10 15

47

Val Leu Gln Ser Met Arg Ala Leu Asp Phe Asn Thr Arg Thr Gln Val
 20 25 30

Thr Arg Glu Ala Ile Ser Leu Val Cys Glu Ala Val Pro Gly Ala Lys
 35 40 45

Gly Ala Thr Arg Arg Arg Lys Pro Cys Ser Arg Pro Leu Ser Ser Ile
 50 55 60

Leu Gly Arg Ser Asn Leu Lys Phe Ala Gly Met Pro Ile Thr Leu Thr
 65 70 75 80

Val Ser Thr Ser Ser Leu Asn Leu Met Ala Ala Asp Cys Lys Gln Ile
 85 90 95

Ile Ala Asn His His Met Gln Ser Ile Ser Phe Ala Ser Gly Gly Asp
 100 105 110

Pro Asp Thr Ala Glu Tyr Val Ala Tyr Val Ala Lys Asp Pro Val Asn
 115 120 125

Gln Arg Ala Cys His Ile Leu Glu Cys Pro Glu Gly Leu Ala Gln Asp
 130 135 140

Val Ile Ser Thr Ile Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr
 145 150 155 160

Leu Arg Asn Pro Pro Lys Leu Val Thr Pro His Asp Arg Met Ala Gly
 165 170 175

Phe Asp Gly Ser Ala Trp Asp Lys Glu Glu
 180 185

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1410 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

- (A) NAME/KEY: CDS
 (B) LOCATION: 1..1407

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

CCG GGG TCC GGG GAC GCC GCC GCC GCC GAG TGG ATC CGG AAG GGC Pro Gly Ser Gly Asp Ala Ala Ala Ala Ala Glu Trp Ile Arg Lys Gly 1 5 10 15	48
AGC TTC ATC CAC AAA CCC GCG CAC GGC TGG CTA CAC CCC GAC GCC AGG Ser Phe Ile His Lys Pro Ala His Gly Trp Leu His Pro Asp Ala Arg 20 25 30	96
GTC CTG GGG CCC GGG GTC TCC TAC GTC GTG CGG TAC ATG GGC TGC ATC Val Leu Gly Pro Gly Val Ser Tyr Val Val Arg Tyr Met Gly Cys Ile 35 40 45	144
GAG GTT CTC CGC TCT ATG CGC TCC CTG GAC TTT AAC ACG CGC ACG CAG Glu Val Leu Arg Ser Met Arg Ser Leu Asp Phe Asn Thr Arg Thr Gln 50 55 60	192
GTG ACC AGG GAA GCC ATC AAC CGG CTC CAT GAG GCC GTG CCT GGC GTC Val Thr Arg Glu Ala Ile Asn Arg Leu His Glu Ala Val Pro Gly Val 65 70 75 80	240
CGG GGA TCC TGG AAG AAA AAG GCC CCC AAC AAG GCC CTG GCG TCC GTC Arg Gly Ser Trp Lys Lys Lys Ala Pro Asn Lys Ala Leu Ala Ser Val 85 90 95	288

48

CTG GGC AAG AGC AAC CTT CGC TTT GCC GGC ATG AGC ATC TCC ATC CAC Leu Gly Lys Ser Asn Leu Arg Phe Ala Gly Met Ser Ile Ser Ile His 100 105 110	336
ATC TCC ACT GAT GGC CTC AGC CTC TCC GTG CCT GCC ACG CGC CAG GTC Ile Ser Thr Asp Gly Leu Ser Val Pro Ala Thr Arg Gln Val 115 120 125	384
ATC GCC AAC CAC CAC ATG CCG TCC ATC TCC TTC GCG TCA GGC GGA GAC Ile Ala Asn His His Met Pro Ser Ile Ser Phe Ala Ser Gly Gly Asp 130 135 140	432
ACG GAC ATG ACG GAT TAC GTG GCC TAC GTC GCC AAG GAC CCC ATC AAC Thr Asp Met Thr Asp Tyr Val Ala Tyr Val Ala Lys Asp Pro Ile Asn 145 150 155 160	480
CAG AGA GCC TGC CAC ATC CTG GAG TGC TGT GAG GGC CTG GCA CAG AGC Gln Arg Ala Cys His Ile Leu Glu Cys Cys Glu Gly Leu Ala Gln Ser 165 170 175	528
ATC ATC AGC ACC GTG GGC CAA GCT TTC GAG CTG CGC TTC AAG CAG TAC Ile Ile Ser Thr Val Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr 180 185 190	576
CTG CAC AGC CCG CCC AAG GTG GCG CTG CCC CCA GAA AGG CTG GCA GGG Leu His Ser Pro Pro Lys Val Ala Leu Pro Pro Glu Arg Leu Ala Gly 195 200 205	624
CCG GAG GAG TCG GCC TGG GGG GAC GAG GAG GAC TCT TTG GAG CAC AAT Pro Glu Glu Ser Ala Trp Gly Asp Glu Glu Asp Ser Leu Glu His Asn 210 215 220	672
TAC TAC AAC AGC ATC CCG GGG AAG GAG CCG CCG CTG GGC GGG CTA GTG Tyr Tyr Asn Ser Ile Pro Gly Lys Glu Pro Pro Leu Gly Gly Leu Val 225 230 235 240	720
GAC TCC AGG CTG GCC CTG ACA CAG CCC TGC GCC CTC ACG GCC CTC GAC Asp Ser Arg Leu Ala Leu Thr Gln Pro Cys Ala Leu Thr Ala Leu Asp 245 250 255	768
CAG GGC CCA TCT CCT TCT CTA AGA GAT GCC TGC AGC CTG CCA TGG GAC Gln Gly Pro Ser Pro Ser Leu Arg Asp Ala Cys Ser Leu Pro Trp Asp 260 265 270	816
GTG GGG TCC ACC GGT ACA GCT CCA CCG GGG GAC GGC TAC GTG CAG GCG Val Gly Ser Thr Gly Thr Ala Pro Pro Gly Asp Gly Tyr Val Gln Ala 275 280 285	864
GAC GCC CCG GGC CCC CCG GAC CAC GAG GAG CAC CTG TAT GTC AAC ACC Asp Ala Arg Gly Pro Pro Asp His Glu Glu His Leu Tyr Val Asn Thr 290 295 300	912
CAG GGT CTG GAC GCC CCC GAG CCG GAG GAC AGC CCC AAA AAG GAT CTG Gln Gly Leu Asp Ala Pro Glu Pro Glu Asp Ser Pro Lys Lys Asp Leu 305 310 315 320	960
TTT GAC ATG CGA CCC TTT GAG GAT GCC CTG AAG TTG CAT GAG TGC TCA Phe Asp Met Arg Pro Phe Glu Asp Ala Leu Lys Leu His Glu Cys Ser 325 330 335	1008

GTG GCG GCA GGC GTG ACA GCA GCC CCT CTT CCC TTG GAG GAC CAG TGG 1056
 Val Ala Ala Gly Val Thr Ala Ala Pro Leu Pro Leu Glu Asp Gln Trp
 340 345 350
 CCC AGC CCC CCT ACC CGC CGG GCC CCT GTG GCC CCC ACG GAG GAA CAG 1104
 Pro Ser Pro Pro Thr Arg Arg Ala Pro Val Ala Pro Thr Glu Glu Gln
 355 360 365
 CTG CGT CAG GAG CCC TGG TAC CAC GGC CGG ATG AGC CGC CGG GCG GCA 1152
 Leu Arg Gln Glu Pro Trp Tyr His Gly Arg Met Ser Arg Arg Ala Ala
 370 375 380
 GAG AGG ATG CTT CGA GCT GAC GGG GAC TTC CTT GTG CGA GAC AGC GTC 1200
 Glu Arg Met Leu Arg Ala Asp Gly Asp Phe Leu Val Arg Asp Ser Val
 385 390 395 400
 ACC AAC CCC GGG CAG TAT GTC CTC ACC GGC ATG CAC GCC GGG CAG CCC 1248
 Thr Asn Pro Gly Gln Tyr Val Leu Thr Gly Met His Ala Gly Gln Pro
 405 410 415
 AAG CAC CTG CTG CTC GTG GAC CCC GAG GGC GTG GTA CGG ACG AAG GAC 1296
 Lys His Leu Leu Leu Val Asp Pro Glu Gly Val Val Arg Thr Lys Asp
 420 425 430
 GTG CTG TTT GAG AGC ATC AGC CAC CTG ATC GAC CAC CAC CTG CAG AAC 1344
 Val Leu Phe Glu Ser Ile Ser His Leu Ile Asp His His Leu Gln Asn
 435 440 445
 GGG CAG CCC ATC GTG GCC GCC GAG AGT GAG CTG CAC CTG CGT GGC GTG 1392
 Gly Gln Pro Ile Val Ala Ala Glu Ser Glu Leu His Leu Arg Gly Val
 450 455 460
 GTC TCA CGG GAG CCC TGA 1410
 Val Ser Arg Glu Pro
 465

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 469 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Pro Gly Ser Gly Asp Ala Ala Ala Ala Glu Trp Ile Arg Lys Gly
 1 5 10 15
 Ser Phe Ile His Lys Pro Ala His Gly Trp Leu His Pro Asp Ala Arg
 20 25 30
 Val Leu Gly Pro Gly Val Ser Tyr Val Val Arg Tyr Met Gly Cys Ile
 35 40 45
 Glu Val Leu Arg Ser Met Arg Ser Leu Asp Phe Asn Thr Arg Thr Gln
 50 55 60
 Val Thr Arg Glu Ala Ile Asn Arg Leu His Glu Ala Val Pro Gly Val
 65 70 75 80
 Arg Gly Ser Trp Lys Lys Lys Ala Pro Asn Lys Ala Leu Ala Ser Val
 85 90 95
 Leu Gly Lys Ser Asn Leu Arg Phe Ala Gly Met Ser Ile Ser Ile His
 100 105 110
 Ile Ser Thr Asp Gly Leu Ser Leu Ser Val Pro Ala Thr Arg Gln Val
 115 120 125
 Ile Ala Asn His His Met Pro Ser Ile Ser Phe Ala Ser Gly Gly Asp
 130 135 140

50

Thr Asp Met Thr Asp Tyr Val Ala Tyr Val Ala Lys Asp Pro Ile Asn
 145 150 155 160
 Gln Arg Ala Cys His Ile Leu Glu Cys Cys Glu Gly Leu Ala Gln Ser
 165 170 175
 Ile Ile Ser Thr Val Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr
 180 185 190
 Leu His Ser Pro Pro Lys Val Ala Leu Pro Pro Glu Arg Leu Ala Gly
 195 200 205
 Pro Glu Glu Ser Ala Trp Gly Asp Glu Glu Asp Ser Leu Glu His Asn
 210 215 220
 Tyr Tyr Asn Ser Ile Pro Gly Lys Glu Pro Pro Leu Gly Gly Leu Val
 225 230 235 240
 Asp Ser Arg Leu Ala Leu Thr Gln Pro Cys Ala Leu Thr Ala Leu Asp
 245 250 255
 Gln Gly Pro Ser Pro Ser Leu Arg Asp Ala Cys Ser Leu Pro Trp Asp
 260 265 270
 Val Gly Ser Thr Gly Thr Ala Pro Pro Gly Asp Gly Tyr Val Gln Ala
 275 280 285
 Asp Ala Arg Gly Pro Pro Asp His Glu Glu His Leu Tyr Val Asn Thr
 290 295 300
 Gln Gly Leu Asp Ala Pro Glu Pro Glu Asp Ser Pro Lys Lys Asp Leu
 305 310 315 320
 Phe Asp Met Arg Pro Phe Glu Asp Ala Leu Lys Leu His Glu Cys Ser
 325 330 335
 Val Ala Ala Gly Val Thr Ala Ala Pro Leu Pro Leu Glu Asp Gln Trp
 340 345 350
 Pro Ser Pro Pro Thr Arg Arg Ala Pro Val Ala Pro Thr Glu Glu Gln
 355 360 365
 Leu Arg Gln Glu Pro Trp Tyr His Gly Arg Met Ser Arg Arg Ala Ala
 370 375 380
 Glu Arg Met Leu Arg Ala Asp Gly Asp Phe Leu Val Arg Asp Ser Val
 385 390 395 400
 Thr Asn Pro Gly Gln Tyr Val Leu Thr Gly Met His Ala Gly Gln Pro
 405 410 415
 Lys His Leu Leu Leu Val Asp Pro Glu Gly Val Val Arg Thr Lys Asp
 420 425 430
 Val Leu Phe Glu Ser Ile Ser His Leu Ile Asp His His Leu Gln Asn
 435 440 445
 Gly Gln Pro Ile Val Ala Ala Glu Ser Glu Leu His Leu Arg Gly Val
 450 455 460
 Val Ser Arg Glu Pro
 465

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1425 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 1..1422

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

ATG AAC AAG CTG AGT GGA GGC GGC GGG CGC AGG ACT CGG GTG GAA GGG Met Asn Lys Leu Ser Gly Gly Gly Gly Arg Arg Thr Arg Val Glu Gly 1 5 10 15	48
GGC CAG CTT GGG GGC GAG GAG TGG ACC CGC CAC GGG AGC TTT GTC AAT Gly Gln Leu Gly Gly Glu Glu Trp Thr Arg His Gly Ser Phe Val Asn 20 25 30	96
AAG CCC ACG CGG GGC TGG CTG CAT CCC AAC GAC AAA GTC ATG GGA CCC Lys Pro Thr Arg Gly Trp Leu His Pro Asn Asp Lys Val Met Gly Pro 35 40 45	144
GGG GTT TCC TAC TTG GTT CGG TAC ATG GGT TGT GTG GAG GTC CTC CAG Gly Val Ser Tyr Leu Val Arg Tyr Met Gly Cys Val Glu Val Leu Gln 50 55 60	192
TCA ATG CGT GCC CTG GAC TTC AAC ACC CGG ACT CAG GTC ACC AGG GAG Ser Met Arg Ala Leu Asp Phe Asn Thr Arg Thr Gln Val Thr Arg Glu 65 70 75 80	240
GCC ATC AGT CTG GTG TGT GAG GCT GTG CCG GGT GCT AAG GGG GCG ACA Ala Ile Ser Leu Val Cys Glu Ala Val Pro Gly Ala Lys Gly Ala Thr 85 90 95	288
AGG AGG AGA AAG CCC TGT AGC CGC CCG CTC AGC TCT ATC CTG GGG AGG Arg Arg Arg Lys Pro Cys Ser Arg Pro Leu Ser Ser Ile Leu Gly Arg 100 105 110	336
AGT AAC CTG AAA TTT GCT GGA ATG CCA ATC ACT CTC ACC GTC TCC ACC Ser Asn Leu Lys Phe Ala Gly Met Pro Ile Thr Leu Thr Val Ser Thr 115 120 125	384
AGC AGC CTC AAC CTC ATG GCC GCA GAC TGC AAA CAG ATC ATC GCC AAC Ser Ser Leu Asn Leu Met Ala Ala Asp Cys Lys Gln Ile Ile Ala Asn 130 135 140	432
CAC CAC ATG CAA TCT ATC TCA TTT GCA TCC GGC GGG GAT CCG GAC ACA His His Met Gln Ser Ile Ser Phe Ala Ser Gly Gly Asp Pro Asp Thr 145 150 155 160	480
GCC GAG TAT GTC GCC TAT GTT GCC AAA GAC CCT GTG AAT CAG AGA GCC Ala Glu Tyr Val Ala Tyr Val Ala Lys Asp Pro Val Asn Gln Arg Ala 165 170 175	528
TGC CAC ATT CTG GAG TGT CCC GAA GGG CTT GCC CAG GAT GTC ATC AGC Cys His Ile Leu Glu Cys Pro Glu Gly Leu Ala Gln Asp Val Ile Ser 180 185 190	576
ACC ATT GGC CAG GCC TTC GAG TTG CGC TTC AAA CAA TAC CTC AGG AAC Thr Ile Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr Leu Arg Asn 195 200 205	624
CCA CCC AAA CTG GTC ACC CCT CAT GAC AGG ATG GCT GGC TTT GAT GGC Pro Pro Lys Leu Val Thr Pro His Asp Arg Met Ala Gly Phe Asp Gly 210 215 220	672
TCA GCA TGG GAT GAG GAG GAG GAA GAG CCA CCT GAC CAT CAG TAC TAT Ser Ala Trp Asp Glu Glu Glu Glu Pro Pro Asp His Gln Tyr Tyr 225 230 235 240	720
AAT GAC TTC CCG GGG AAG GAA CCC CCC TTG GGG GGG GTG GTA GAC ATG Asn Asp Phe Pro Gly Lys Glu Pro Pro Leu Gly Gly Val Val Asp Met 245 250 255	768
AGG CTT CGG GAA GGA GCC GCT CCA GGG GCT GCT CGA CCC ACT GCA CCC Arg Leu Arg Glu Gly Ala Ala Pro Gly Ala Ala Arg Pro Thr Ala Pro 260 265 270	816

52

AAT GCC CAG ACC CCC AGC CAC TTG GGA GCT ACA TTG CCT GTA GGA CAG Asn Ala Gln Thr Pro Ser His Leu Gly Ala Thr Leu Pro Val Gly Gln 275 280 285	864
CCT GTT GGG GGA GAT CCA GAA GTC CGC AAA CAG ATG CCA CCT CCA CCA Pro Val Gly Gly Asp Pro Glu Val Arg Lys Gln Met Pro Pro Pro Pro 290 295 300	912
CCC TGT CCA GCA GGC AGA GAG CTT TTT GAT GAT CCC TCC TAT GTC AAC Pro Cys Pro Ala Gly Arg Glu Leu Phe Asp Asp Pro Ser Tyr Val Asn 305 310 315 320	960
GTC CAG AAC CTA GAC AAG GCC CGG CAA GCA GTG GGT GGT GCT GGG CCC Val Gln Asn Leu Asp Lys Ala Arg Gln Ala Val Gly Gly Ala Gly Pro 325 330 335	1008
CCC AAT CCT GCT ATC AAT GGC AGT GCA CCC CGG GAC CTG TTT GAC ATG Pro Asn Pro Ala Ile Asn Gly Ser Ala Pro Arg Asp Leu Phe Asp Met 340 345 350	1056
AAG CCC TTC GAA GAT GCT CTT CGG GTG CCT CCA CCT CCC CAG TCG GTG Lys Pro Phe Glu Asp Ala Leu Arg Val Pro Pro Pro Pro Gln Ser Val 355 360 365	1104
TCC ATG GCT GAG CAG CTC CGA GGG GAG CCC TGG TTC CAT GGG AAG CTG Ser Met Ala Glu Gln Leu Arg Gly Glu Pro Trp Phe His Gly Lys Leu 370 375 380	1152
AGC CGG CGG GAG GCT GAG GCA CTG CTG CAG CTC AAT GGG GAC TTC CTG Ser Arg Arg Glu Ala Glu Ala Leu Leu Gln Leu Asn Gly Asp Phe Leu 385 390 395 400	1200
GTA CGG GAG AGC ACG ACC ACA CCT GGC CAG TAT GTG CTC ACT GGC TTG Val Arg Glu Ser Thr Thr Thr Pro Gly Gln Tyr Val Leu Thr Gly Leu 405 410 415	1248
CAG AGT GGG CAG CCT AAG CAT TTG CTA CTG GTG GAC CCT GAG GGT GTG Gln Ser Gly Gln Pro Lys His Leu Leu Leu Val Asp Pro Glu Gly Val 420 425 430	1296
GTT CGG ACT AAG GAT CAC CGC TTT GAA AGT GTC AGT CAC CTT ATC AGC Val Arg Thr Lys Asp His Arg Phe Glu Ser Val Ser His Leu Ile Ser 435 440 445	1344
TAC CAC ATG GAC AAT CAC TTG CCC ATC ATC TCT GCG GGC AGC GAA CTG Tyr His Met Asp Asn His Leu Pro Ile Ile Ser Ala Gly Ser Glu Leu 450 455 460	1392
TGT CTA CAG CAA CCT GTG GAG CGG AAA CTG TGA Cys Leu Gln Gln Pro Val Glu Arg Lys Leu 465 470	1425

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 474 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

Met Asn Lys Leu Ser Gly Gly Gly Gly Arg Arg Thr Arg Val Glu Gly 1 5 10 15
Gly Gln Leu Gly Gly Glu Glu Trp Thr Arg His Gly Ser Phe Val Asn 20 25 30
Lys Pro Thr Arg Gly Trp Leu His Pro Asn Asp Lys Val Met Gly Pro 35 40 45

53

Gly Val Ser Tyr Leu Val Arg Tyr Met Gly Cys Val Glu Val Leu Gln
 50 55 60
 Ser Met Arg Ala Leu Asp Phe Asn Thr Arg Thr Gln Val Thr Arg Glu
 65 70 75 80
 Ala Ile Ser Leu Val Cys Glu Ala Val Pro Gly Ala Lys Gly Ala Thr
 85 90 95
 Arg Arg Arg Lys Pro Cys Ser Arg Pro Leu Ser Ser Ile Leu Gly Arg
 100 105 110
 Ser Asn Leu Lys Phe Ala Gly Met Pro Ile Thr Leu Thr Val Ser Thr
 115 120 125
 Ser Ser Leu Asn Leu Met Ala Ala Asp Cys Lys Gln Ile Ile Ala Asn
 130 135 140
 His His Met Gln Ser Ile Ser Phe Ala Ser Gly Gly Asp Pro Asp Thr
 145 150 155 160
 Ala Glu Tyr Val Ala Tyr Val Ala Lys Asp Pro Val Asn Gln Arg Ala
 165 170 175
 Cys His Ile Leu Glu Cys Pro Glu Gly Leu Ala Gln Asp Val Ile Ser
 180 185 190
 Thr Ile Gly Gln Ala Phe Glu Leu Arg Phe Lys Gln Tyr Leu Arg Asn
 195 200 205
 Pro Pro Lys Leu Val Thr Pro His Asp Arg Met Ala Gly Phe Asp Gly
 210 215 220
 Ser Ala Trp Asp Glu Glu Glu Glu Glu Pro Pro Asp His Gln Tyr Tyr
 225 230 235 240
 Asn Asp Phe Pro Gly Lys Glu Pro Pro Leu Gly Gly Val Val Asp Met
 245 250 255
 Arg Leu Arg Glu Gly Ala Ala Pro Gly Ala Ala Arg Pro Thr Ala Pro
 260 265 270
 Asn Ala Gln Thr Pro Ser His Leu Gly Ala Thr Leu Pro Val Gly Gln
 275 280 285
 Pro Val Gly Gly Asp Pro Glu Val Arg Lys Gln Met Pro Pro Pro Pro
 290 295 300
 Pro Cys Pro Ala Gly Arg Glu Leu Phe Asp Asp Pro Ser Tyr Val Asn
 305 310 315 320
 Val Gln Asn Leu Asp Lys Ala Arg Gln Ala Val Gly Gly Ala Gly Pro
 325 330 335
 Pro Asn Pro Ala Ile Asn Gly Ser Ala Pro Arg Asp Leu Phe Asp Met
 340 345 350
 Lys Pro Phe Glu Asp Ala Leu Arg Val Pro Pro Pro Pro Gln Ser Val
 355 360 365
 Ser Met Ala Glu Gln Leu Arg Gly Glu Pro Trp Phe His Gly Lys Leu
 370 375 380
 Ser Arg Arg Glu Ala Glu Ala Leu Leu Gln Leu Asn Gly Asp Phe Leu
 385 390 395 400
 Val Arg Glu Ser Thr Thr Thr Pro Gly Gln Tyr Val Leu Thr Gly Leu
 405 410 415
 Gln Ser Gly Gln Pro Lys His Leu Leu Leu Val Asp Pro Glu Gly Val
 420 425 430
 Val Arg Thr Lys Asp His Arg Phe Glu Ser Val Ser His Leu Ile Ser
 435 440 445

54

Tyr His Met Asp Asn His Leu Pro Ile Ile Ser Ala Gly Ser Glu Leu
450 455 460

Cys Leu Gln Gln Pro Val Glu Arg Lys Leu
465 470

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 8 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(ix) FEATURE:

- (A) NAME/KEY: Region
- (B) LOCATION: one-of(2)
- (D) OTHER INFORMATION: /note= "Xaa is Ser or Thr."

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Gly Xaa Phe Leu Val Arg Glu Ser
1 5

WHAT IS CLAIMED IS:

1. An isolated polypeptide, said polypeptide comprising a non-SH2 phosphotyrosine binding domain, said
5 non-SH2 phosphotyrosine binding domain comprising an amino acid sequence of a SCK phosphotyrosine binding domain, as shown in Figure 4, or a phosphotyrosine binding fragment thereof.
- 10 2. The isolated polypeptide of claim 1, wherein said polypeptide further comprises a heterologous protein fused to said polypeptide.
3. The isolated polypeptide of claim 1,
15 wherein said polypeptide is covalently linked to a detectable group.
4. The isolated polypeptide of claim 3, wherein said detectable group is a radiolabel.
20
5. The isolated polypeptide of claim 3, wherein said detectable group is an enzyme.
6. An isolated polypeptide, said polypeptide
25 consisting essentially of an amino acid sequence identical to or substantially homologous to an amino acid sequence of a SHC phosphotyrosine binding domain, as shown in Figure 4, or a phosphotyrosine binding fragment thereof.
- 30 7. An isolated polypeptide, said polypeptide comprising a non-SH2 phosphotyrosine binding domain covalently linked to a detectable group, said phosphotyrosine binding domain consisting essentially of
35 the amino acid sequence of an SHC phosphotyrosine binding domain, as shown in Figure 4, or a phosphotyrosine binding fragment thereof.

8. The isolated polypeptide of claim 7, wherein said detectable group is a radiolabel.

9. The isolated polypeptide of claim 7, wherein said detectable group is an enzyme.

10. An isolated fusion protein, said fusion protein comprising a non-SH2 phosphotyrosine binding domain fused to a heterologous protein, said phosphotyrosine binding domain consisting essentially of the amino acid sequence of an SHC phosphotyrosine binding domain, as shown in Figure 4, or a phosphotyrosine binding fragment thereof.

11. An isolated nucleic acid, said nucleic acid comprising a nucleotide sequence which encodes a SCK phosphotyrosine binding domain, as shown in Figure 5, or a fragment thereof.

12. The isolated nucleic acid of claim 11, wherein said nucleic acid further comprises a segment which encodes a heterologous protein.

13. The isolated nucleic acid of claim 11, said nucleic acid comprising at least 15 consecutive nucleotides of a nucleotide sequence which encodes a SCK phosphotyrosine binding domain, as shown in Figure 5.

14. The nucleic acid of claim 13, wherein said nucleic acid is covalently linked to a detectable group.

15. The nucleic acid of claim 14, wherein said detectable group is selected from a radiolabel and a fluorescent group.

16. An isolated nucleic acid, said nucleic acid consisting essentially of a nucleotide sequence substantially homologous to a nucleotide sequence which encodes a SHC phosphotyrosine binding domain, as shown in Figure 6, or a fragment thereof.

17. An isolated nucleic acid, said nucleic acid comprising a segment which encodes a phosphotyrosine binding domain fused to a segment which encodes a heterologous protein, said segment which encodes said phosphotyrosine binding domain consisting essentially of the nucleotide sequence which encodes a SHC phosphotyrosine binding domain, as shown in Figure 6, or a fragment thereof.

15

18. A nucleic acid probe, said probe comprising a nucleic acid segment covalently linked to a detectable group, said nucleic acid segment consisting essentially of at least 15 consecutive nucleotides of a sequence which encodes a SHC phosphotyrosine binding domain, as shown in Figure 6.

19. The nucleic acid probe of claim 18, wherein said detectable group is selected from a radiolabel and a fluorescent group.

20. An expression vector, said expression vector comprising a nucleic acid operably linked to a promoter sequence, wherein said nucleic acid is the nucleic acid of claim 11, 16, or 17.

21. A method of preparing a polypeptide capable of binding a tyrosine-phosphorylated protein, wherein the polypeptide comprises a non-SH2 PTB domain, and whereby the binding of the polypeptide to the tyrosine-phosphorylated protein is through the non-SH2 PTB domain comprising:

inserting the nucleic acid of claims 11, 16, or 17, into an expression vector;

transfecting a host cell capable of expressing said nucleic acid with said expression vector to express said polypeptide comprising said non-SH2 PTB domain; and

recovering said expressed polypeptide comprising non-SH2 PTB domain.

22. A recombinant host cell, wherein said host cell has been transfected with the expression vector of claim 20, whereby said cell is capable of expressing said nucleic acid.

23. The recombinant host cell of claim 22, wherein said host cell is selected from an Sf9 insect cell and *E. coli*.

24. The method of claim 21, wherein said expression vector is the pV-IKS baculovirus expression vector, and said host cell is an Sf9 insect cell.

25. A method of determining whether a protein is a phosphorylated ligand of a PTB domain, the method comprising contacting the protein with the polypeptide of claims 1, 6, 7, or 10, and detecting the binding of the polypeptide to the protein, the binding of the polypeptide to the protein being indicative that the protein is a phosphorylated ligand of the PTB domain.

26. The method of claim 25, wherein the protein is attached to a solid support;

the polypeptide further comprises a detectable group fused to the polypeptide; and

the detecting of the binding of the polypeptide to the protein is by assaying for the presence of the detectable group.

27. The method of claim 25, wherein said polypeptide is attached to a solid support.

28. A method of determining whether a test
5 compound is an antagonist of a growth factor activation signaling pathway in a cell, comprising:

contacting the cell with the test compound
in the presence of a growth factor;

lysing the cell; and

10 assaying the cell lysate to determine whether any protein in the lysate is a phosphorylated ligand to a PTB domain, according to the method of claim 25, the absence of said phosphorylated ligand being indicative that the compound is an antagonist of the
15 growth factor activation signaling pathway.

29. A method of determining if a test compound is an agonist or antagonist of PTB domain/phosphorylated ligand regulatory system, the method comprising:

20 incubating the test compound with a polypeptide comprising a PTB domain, and a phosphorylated ligand which is capable of interacting with said PTB domain to form a PTB domain/phosphorylated ligand complex, under conditions which permit the formation of
25 said complex;

determining the amount of PTB domain/phosphorylated ligand complex formed, and comparing that amount to the amount of PTB domain/phosphorylated ligand complex formed in the absence of the test compound;

30 the increase or decrease in the amount of complex formed in the presence of the test compound over the amount of complex formed in the absence of the test compound being indicative that the test compound is an agonist or antagonist of the PTB domain/phosphorylated
35 ligand regulatory system.

30. A method of blocking growth factor dependent stimulation of cells, comprising contacting the cells with an effective amount of the polypeptide of claims 1, 6 or 10.

5

31. A method of obtaining substantially pure phosphorylated ligand to a PTB domain from a mixture of different proteins comprising contacting the mixture of different proteins with a PTB domain immobilized on a solid support, whereby the phosphorylated ligand is bound to the PTB domain;

washing the solid support to remove unbound proteins;

eluting the phosphorylated ligand from the solid support.

32. A method for treating a patient suffering from a proliferative cell disorder, comprising administering to said patient, an effective amount of the polypeptide of claim 1, 6 or 10.

33. The method of claim 32, wherein said proliferative cell disorder is selected from the group consisting of atherosclerosis, inflammatory joint disease, psoriasis, restinosis, and cancer.


34. A method for treating a patient suffering from a proliferative cell disorder, said method comprising

explanting cells from the patient;
transfecting the cells with a nucleic acid encoding a polypeptide, said polypeptide comprising a non-SH2 PTB domain;

selecting for cells which have incorporated said nucleic acid; and

reimplanting the cells into the patient.

FIG. 1



2/10

FIG. 2A




FIG. 2B




FIG. 2C




FIG. 2D




FIG. 3A





FIG. 3B



4/10

FIG. 4

SCK	..pgsGdaaa aaEWiRkGSF ihKPahGWLH PdarV	IGPGV SYvVRYMGci
SHC	rtrveGggig geEWtRhGSF vnKPtrGWLH PndkV	mGPGV SYIVRYMGcv
SCK	EVLrSMRsLD FNTRTQVTRE AInrihEAVP GvrGs.wkkK apnkaLaSvL	
SHC	EVLqSMRaLD FNTRTQVTRE AIslvcEAVP GakGatrerrK pcsrpLsSiL	
SCK	GkSNLrFAGM sIsihiSTdg LsLsvpatrQ vLANHHMpSI SFASGGDtDm	
SHC	GrSNLkFAGM pItltvSTss LnLmaadckQ iLANHHMqSI SFASGGDpDt	
SCK	tdYVAYVAKD PiNQRACHIL ECcEGLAQsi ISTvGQAFEL RFKQYLhsPP	
SHC	aeYVAYVAKD PvNQRACHIL ECpEGLAQdv ISTiGQAFEL RFKQYLrnPP	
SCK	KvaIPpeRlA GpeeSAWg.d EE	EdslEHnYY NsiPGKEPPL GGIVDsRLa1
SHC	KlvtPhdRmA GfdgSAWdEe EE	eppDHqYY NdfPGKEPPL GGvVDMRL..
SCK	tqpcAltaId qgpsPslrda csLpwdvgst GtappGDgyV qadargPPd.	
SHC	.regAapgaa rptaNqatp shLgat1.pv GqpvgGDpeV rkqmpPPpc	
SCKheeh1 YVNtQgLD... .. APEpedSpkk DLFDMrPFED	
SHC	pgrelfddps YVNvQnLDka rqavggagpp NPaingSapr DLFDmkPFED	
SCK	ALklhecsva agvtaaplpl edqwpsPPtr rapvApteEQ LRqEPWyHGr	
SHC	ALrv..... .ppPpq svsmA...EQ LRgEPWfHGK	
SCK	mSRRaAErmL radGDFLVRd SvTnPGQYVL TGmhaGQPKH LLLVDPEGVV	
SHC	1SRReAEa1L qlnGDFLVRd StTtPGQYVL TG1qsGQPKH LLLVDPEGVV	

5/10

FIG. 5A

10 20 30 40 50 60
*
CCGGGGTCCGGGGACGCCGCCGCCGCCGAGTGGATCCGGAAGGGCAGCTTCATCCAC
GGCCCCAGGCCCTGCGGCGGCGGCGGCGGCTCACCTAGGCCTTCCCGTCGAAGTAGGTG
P G S G D A A A A A E W I R K G S F I H>
70 80 90 100 110 120
*
AAACCCGCGCACGGCTGGCTACACCCCGACGCCAGGGTCTGGGGCCCGGGGTCTCCTAC
TTTGGGCGCGTGCCGACCGATGTGGGGCTGCGGTCCCAGGACCCCGGGCCCCAGAGGATG
K P A H G W L H P D A R V L G P G V S Y>
130 140 150 160 170 180
*
GTCGTGCGGTACATGGGCTGCATCGAGGTTCTCCGCTCTATGCGCTCCCTGGACTTTAAC
CAGCACGCCATGTACCCGACGTAGCTCCAAGAGGCGAGATACGCGAGGGACCTGAAATTG
V V R Y M G C I E V L R S M R S L D F N>
190 200 210 220 230 240
*
ACGCGCACGCAGGTGACCAGGGAAGCCATCAACCGGCTCCATGAGGCCGTGCCTGGCGTC
TGCGCGTGCGTCCACTGGTCCCTTCGGTAGTTGGCCGAGGTA CTCCGGCACGGACCGCAG
T R T Q V T R E A I N R L H E A V P G V>
250 260 270 280 290 300
*
CGGGGATCCTGGAAGAAAAAGGCCCCCAACAAGGCCCTGGCGTCCGTCTGGGCAAGAGC
GCCCTAGGACCTTCTTTTTCCGGGGGTTGTTCCGGGACCGCAGGCAGGACCCGTTCTCG
R G S W K K K A P N K A L A S V L G K S>
310 320 330 340 350 360
*
AACCTTCGCTTTGCCGGCATGAGCATCTCCATCCACATCTCCACTGATGGCCTCAGCCTC
TTGGAAGCGAAACGGCCGTACTCGTAGAGGTAGGTGTAGAGGTGACTACCGGAGTCGGAG
N L R F A G M S I S I H I S T D G L S L>
370 380 390 400 410 420
*
TCCGTGCCTGCCACGCGCCAGGTCATCGCCAACCACCACATGCCGTCCATCTCCTTCGCG
AGGCACGGACGGTGCGCGGTCCAGTAGCGGTTGGTGGTGTACGGCAGGTAGAGGAAGCGC
S V P A T R Q V I A N H H M P S I S F A>
430 440 450 460 470 480
*
TCAGGCGGAGACACGGACATGACGGATTACGTGGCCTACGTCGCCAAGGACCCCATCAAC
AGTCCGCCTCTGTGCCTGTACTGCCTAATGCACCGGATGCAGCGGTTCTGGGGTAGTTG
S G G D T D M T D Y V A Y V A K D P I N>
490 500 510 520 530 540
*
CAGAGAGCCTGCCACATCCTGGAGTGCTGTGAGGGCCTGGCACAGAGCATCATCAGCACC
GTCTCTCGGACGGTGTAGGACCTCACGACACTCCCGGACCGTGTCTCGTAGTAGTCGTGG
Q R A C H I L E C C E G L A Q S I I S T>
550 560 570 580 590 600
*
GTGGGCCAAGCTTTTCGAGCTGCGCTTCAAGCAGTACCTGCACAGCCCGCCCAAGGTGGCG
CACCCGGTTCGAAAGCTCGACGCGAAGTTCGTATGGACGTGTCGGGCGGGTTCACCGC
V G Q A F E L R F K Q Y L H S P P K V A>

SUBSTITUTE SHEET (RULE 26)

FIG. 5B

6/10

610 620 630 640 650 660
CTGCCCCCAGAAAGGCTGGCAGGGCCGGAGGAGTCGGCCTGGGGGGACGAGGAGGACTCT
GACGGGGGTCTTTCCGACCGTCCCGGCCTCCTCAGCCGGACCCCCCTGCTCCTCCTGAGA
L P P E R L A G P E E S A W G D E E D S>
670 680 690 700 710 720
TTGGAGCACAACTTACTACAACAGCATCCCGGGGAAGGAGCCGCCGCTGGGCGGGCTAGTG
AACCTCGTGTTAATGATGTTGTGCGTAGGGCCCCTTCCTCGGCGGCGACCCGCCCGATCAC
L E H N Y Y N S I P G K E P P L G G L V>
730 740 750 760 770 780
GACTCCAGGCTGGCCCTGACACAGCCCTGCGCCCTCACGGCCCTCGACCAGGGCCCATCT
CTGAGGTCCGACCGGGACTGTGTGCGGACGCGGGAGTGCCGGGAGCTGGTCCCGGGTAGA
D S R L A L T Q P C A L T A L D Q G P S>
790 800 810 820 830 840
CCTTCTCTAAGAGATGCCTGCAGCCTGCCATGGGACGTGGGGTCCACCGGTACAGCTCCA
GGAAGAGATTCTCTACGGACGTGCGACGGTACCCTGCACCCAGGTGGCCATGTCGAGGT
P S L R D A C S L P W D V G S T G T A P>
850 860 870 880 890 900
CCGGGGGACGGCTACGTGCAGGCGGACGCCCGGGGCCCCCGGACCACGAGGAGCACCTG
GGCCCCCTGCCGATGCACGTCCGCCTGCGGGCCCCGGGGGGCCTGGTGTCTCCTCGTGGAC
P G D G Y V Q A D A R G P P D H E E H L>
910 920 930 940 950 960
TATGTCAACACCCAGGGTCTGGACGCCCCGAGCCGGAGGACAGCCCCAAAAAGGATCTG
ATACAGTTGTGGGTCCAGACCTGCGGGGGCTCGGCCTCCTGTGCGGGGTTTTTCCTAGAC
Y V N T Q G L D A P E P E D S P K K D L>
970 980 990 1000 1010 1020
TTTGACATGCGACCCTTTGAGGATGCCCTGAAGTTGCATGAGTGCTCAGTGGCGGCAGGC
AAACTGTACGCTGGGAACTCCTACGGGACTTCAACGTACTCACGAGTCACCGCCGTCCG
F D M R P F E D A L K L H E C S V A A G>
1030 1040 1050 1060 1070 1080
GTGACAGCAGCCCCTCTTCCCTTGGAGGACCAGTGGCCCAGCCCCCTACCCGCCGGGCC
CACTGTCGTCGGGGAGAAGGGAACCTCCTGGTCACCGGGTCGGGGGGATGGGCGGCCCGG
V T A A P L P L E D Q W P S P P T R R A>
1090 1100 1110 1120 1130 1140
CCTGTGGCCCCACGGAGGAACAGCTGCGTCAGGAGCCCTGGTACCACGGCCGGATGAGC
GGACACCGGGGGTGCCTCCTTGTGACGCAGTCCTCGGGACCATGGTGCCGGCCTACTCG
P V A P T E E Q L R Q E P W Y H G R M S>
1150 1160 1170 1180 1190 1200
CGCCGGGCGGCAGAGAGGATGCTTCGAGCTGACGGGGACTTCCTTGTGCGAGACAGCGTC
GCGGCCCGCCGTCTCTCTACGAAGCTCGACTGCCCTGAAGGAACACGCTCTGTGCAG
R R A A E R M L R A D G D F L V R D S V>

SUBSTITUTE SHEET (RULE 26)

7/10

FIG. 5C

1210	1220	1230	1240	1250	1260
					*
ACCAACCCCGGGCAGTATGTCCTCACCGGCATGCACGCCGGGCAGCCCAAGCACCTGCTG					
TGGTTGGGGCCCGTCATACAGGAGTGGCCGTACGTGCGGCCCGTCGGGGTTCGTGGACGAC					
T N P G Q Y V L T G M H A G Q P K H L L>					
1270	1280	1290	1300	1310	1320
					*
CTCGTGGACCCCGAGGGCGTGGTACGGACGAAGGACGTGCTGTTTGAGAGCATCAGCCAC					
GAGCACCTGGGGCTCCCGCACCATGCCTGCTTCCTGCACGACAAACTCTCGTAGTCGGTG					
L V D P E G V V R T K D V L F E S I S H>					
1330	1340	1350	1360	1370	1380
					*
CTGATCGACCACCACCTGCAGAACGGGCAGCCCATCGTGGCCGCCGAGAGTGAGCTGCAC					
GACTAGCTGGTGGTGGACGTCTTGCCCGTCGGGTAGCACCGGCGGCTCTCACTCGACGTG					
L I D H H L Q N G Q P I V A A E S E L H>					
1390	1400	1410			
CTGCGTGGCGTGGTCTCACGGGAGCCCTGA					
GACGCACCGCACCAGAGTGCCCTCGGGACT					
L R G V V S R E P *>					

FIG. 6A

8/10

10 20 30 40 50 60
ATGAACAAGCTGAGTGGAGGCGGCGGGCGCAGGACTCGGGTGGAAAGGGGGCCAGCTTGGG
TACTTGTTCGACTCACCTCCGCCGCCCGCGTCCTGAGCCCACCTTCCCCCGGTCTGAACCC
M N K L S G G G R R T R V E G G Q L G>
70 80 90 100 110 120
GGCGAGGAGTGGACCCGCCACGGGAGCTTTGTCAATAAGCCACGCGGGGCTGGCTGCAT
CCGCTCCTCACCTGGGCGGTGCCCTCGAAACAGTTATTCGGGTGCGCCCCGACCGACGTA
G E E W T R H G S F V N K P T R G W L H>
130 140 150 160 170 180
CCCAACGACAAAGTCATGGGACCCGGGGTTTCTACTTGGTTCGGTACATGGGTTGTGTG
GGGTTGCTGTTTCAGTACCCTGGGCCCCAAAGGATGAACCAAGCCATGTACCCAACACAC
P N D K V M G P G V S Y L V R Y M G C V>
190 200 210 220 230 240
GAGGTCCTCCAGTCAATGCGTGCCCTGGACTTCAACACCCGGACTCAGGTCACCAGGGAG
CTCCAGGAGGTGAGTTACGCACGGGACCTGAAGTTGTGGGCCTGAGTCCAGTGGTCCCTC
E V L Q S M R A L D F N T R T Q V T R E>
250 260 270 280 290 300
GCCATCAGTCTGGTGTGTGAGGCTGTGCCGGGTGCTAAGGGGGGCGACAAGGAGGAGAAAG
CGGTAGTCAGACCACACACTCCGACACGGCCACGATTCCCCCGCTGTTCTCCTCTTTC
A I S L V C E A V P G A K G A T R R R K>
310 320 330 340 350 360
CCCTGTAGCCGCCCGCTCAGCTCTATCCTGGGGAGGAGTAACCTGAAATTTGCTGGAATG
GGGACATCGGCGGGCGAGTCGAGATAGGACCCCTCCTCATTGGACTTTAAACGACCTTAC
P C S R P L S S I L G R S N L K F A G M>
370 380 390 400 410 420
CCAATCACTCTCACCGTCTCCACCAGCAGCCTCAACCTCATGGCCGCAGACTGCAAACAG
GGTTAGTGAGAGTGGCAGAGGTGGTCGTCGGAGTTGGAGTACCGGCGTCTGACGTTTGTG
P I T L T V S T S S L N L M A A D C K Q>
430 440 450 460 470 480
ATCATCGCCAACCACCACATGCAATCTATCTCATTTGCATCCGGCGGGGATCCGGACACA
TAGTAGCGGTTGGTGGTGTACGTTAGATAGAGTAAACGTAGGCCGCCCTAGGCCTGTGT
I I A N H H M Q S I S F A S G G D P D T>
490 500 510 520 530 540
GCCGAGTATGTCGCCTATGTTGCCAAAGACCCTGTGAATCAGAGAGCCTGCCACATTCTG
CGGCTCATACAGCGGATACAACGGTTTCTGGGACACTTAGTCTCTCGGACGGTGTAAAGAC
A E Y V A Y V A K D P V N Q R A C H I L>
550 560 570 580 590 600
GAGTGTCCCGAAGGGCTTGCCCAGGATGTCATCAGCACCATTTGGCCAGGCCTTCGAGTTG
CTCACAGGGCTTCCCGAACGGGTCTACAGTAGTCGTGGTAACCGGTCCGGAAGCTCAAC
E C P E G L A Q D V I S T I G Q A F E L>

FIG. 6B

9/10

610 620 630 640 650 660
*
CGCTTCAAACAATACCTCAGGAACCCACCCAACTGGTCACCCCTCATGACAGGATGGCT
CGGAAGTTTGTATGGAGTCCTTGGGTGGGTTTGACCAAGTGGGGAGTACTGTCCTACCGA
R F K Q Y L R N P P K L V T P H D R M A>
670 680 690 700 710 720
*
GGCTTTGATGGCTCAGCATGGGATGAGGAGGAGGAAGAGCCACCTGACCATCAGTACTAT
CCGAAACTACCGAGTCGTACCCTACTCCTCCTCCTTCTCGGTGGACTGGTAGTCATGATA
G F D G S A W D E E E E E P P D H Q Y Y>
730 740 750 760 770 780
*
AATGACTTCCCGGGGAAGGAACCCCCCTTGGGGGGGGTGGTAGACATGAGGCTTCGGGAA
TTACTGAAGGGCCCTTCTTGGGGGGAACCCCCCCCACCATCTGTACTCCGAAGCCCTT
N D F P G K E P P L G G V V D M R L R E>
790 800 810 820 830 840
*
GGAGCCGCTCCAGGGGCTGCTCGACCCACTGCACCCAATGCCAGACCCCCAGCCACTTG
CCTCGGCGAGGTCCCCGACGAGCTGGGTGACGTGGGTTACGGGTCTGGGGGTGGGTGAAC
G A A P G A A R P T A P N A Q T P S H L>
850 860 870 880 890 900
*
GGAGCTACATTGCCTGTAGGACAGCCTGTTGGGGGAGATCCAGAAGTCCGCAAACAGATG
CCTCGATGTAACGGACATCCTGTGCGACAACCCCCTCTAGGTCTTCAGGCGTTTGTCTAC
G A T L P V G Q P V G G D P E V R K Q M>
910 920 930 940 950 960
*
CCACCTCCACCACCCTGTCCAGCAGGCAGAGAGCTTTTTGATGATCCCTCCTATGTCAAC
GGTGGAGGTGGTGGGACAGGTCGTCCGTCTCTCGAAAACTACTAGGGAGGATACAGTTG
P P P P P C P A G R E L F D D P S Y V N>
970 980 990 1000 1010 1020
*
GTCCAGAACCTAGACAAGGCCCGGCAAGCAGTGGGTGGTGCTGGGCCCCCAATCCTGCT
CAGGTCTTGATCTGTTCCGGGCCGTTTCGTACCCACCACGACCCGGGGGGTTAGGACGA
V Q N L D K A R Q A V G G A G P P N P A>
1030 1040 1050 1060 1070 1080
*
ATCAATGGCAGTGCACCCCGGGACCTGTTTGACATGAAGCCCTTCGAAGATGCTCTTCGG
TAGTTACCGTCACGTGGGGCCCTGGACAACTGTACTTCGGGAAGCTTCTACGAGAAGCC
I N G S A P R D L F D M K P F E D A L R>
1090 1100 1110 1120 1130 1140
*
GTGCCTCCACCTCCCCAGTCGGTGTCCATGGCTGAGCAGCTCCGAGGGGAGCCCTGGTTC
CACGGAGGTGGAGGGGTGAGCCACAGGTACCGACTCGTCGAGGCTCCCCTCGGGACCAAG
V P P P P Q S V S M A E Q L R G E P W F>
1150 1160 1170 1180 1190 1200
*
CATGGGAAGCTGAGCCGGCGGGAGGCTGAGGCACTGCTGCAGCTCAATGGGGACTTCCTG
CTACCCTTCGACTCGGCCGCCCTCCGACTCCGTGACGACGTGAGTTACCCCTGAAGGAC
H G K L S R R E A E A L L Q L N G D F L>

SUBSTITUTE SHEET (RULE 26)

10/10

FIG. 6C

1210	1220	1230	1240	1250	1260
GTACGGGAGAGCACGACCACACCTGGCCAGTATGTGCTCACTGGCTTGCAGAGTGGGCAG*					
CATGCCCTCTCGTGCTGGTGTGGACCGGTCATACACGAGTGACCGAACGTCTCACCCGTC					
V R E S T T T P G Q Y V L T G L Q S G Q>					
1270	1280	1290	1300	1310	1320
CCTAAGCATTGCTACTGGTGGACCCTGAGGGTGTGGTTCGGACTAAGGATCACCGCTTT*					
GGATTTCGTAAACGATGACCACCTGGGACTCCCACACCAAGCCTGATTCTAGTGGCGAAA					
P K H L L L V D P E G V V R T K D H R F>					
1330	1340	1350	1360	1370	1380
GAAAGTGTGAGTCACCTTATCAGCTACCACATGGACAATCACTTGCCCATCATCTCTGCG*					
CTTTCACAGTCAGTGGGAATAGTCGATGGTGTACCTGTTAGTGAACGGGTAGTAGAGACGC					
E S V S H L I S Y H M D N H L P I I S A>					
1390	1400	1410	1420		
GGCAGCGAACTGTGTCTACAGCAACCTGTGGAGCGGAACTGTGA					
CCGTCGCTTGACACAGATGTCGTTGGACACCTCGCCTTTGACACT					
G S E L C L Q Q P V E R K L *>					

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/15144**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) : C07K 14/47; C12N 5/10, 15/12, 15/62

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 69.1, 69.7, 172.3, 252.3, 320.1; 514/2; 530/350; 536/23.4, 23.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, STN/MEDLINE

search terms: epidermal growth factor receptor, phosphoryl?, substrate, SHC, SCK

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X --- Y --- A	Cell, Volume 70, issued 10 July 1992, PELICCI et al., "A Novel Transforming Protein (SHC) with an SH2 Domain is Implicated in Mitogenic Signal Transduction", pages 93-104, see especially Figures 1B and 1C on page 95.	6-8, 16, 20 ----- 9, 10, 17-19, 21-34 ----- 1-5, 11-15
Y --- A	Blood, Volume 82, Number 8, issued 15 October 1993, DAMEN et al. "Erythropoietin Stimulates the Tyrosine Phosphorylation of Shc and its Association With Grb2 and a 145-Kd Tyrosine Phosphorylated Protein", pages 2296-2303, see entire document.	21, 24-34 ----- 1-5, 11-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

26 MARCH 1996

Date of mailing of the international search report

04 APR 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JOHN D. ULM

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/15144

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/6, 69.1, 69.7, 172.3, 252.3, 320.1; 514/2; 530/350; 536/23.4, 23.5